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Background: Previous studies have addressed multiple sclerosis (MS) symptom 
management and improved health-related quality of life (HrQOL).  Yet lowered estrogen 
levels in post-menopasual women with MS may further worsen physical function and 
symptomology and not all types of pain management have been examined. 
Objectives:  For post-menopausal women with MS, we evaluated the extent to which 
smoking is associated with worsened health outcomes and HrQOL, and the extent to 
which menopausal hormone treatment (MHT) improves health outcomes and HrQOL.  
For all adult men and women with clinically diagnosed MS, we systematically reviewed 
pharmacological and non-pharmacological strategies for the reduction of pain. 
 
 
Methods: We identified 256 post-menopausal women with MS in the Women's Health 
Initiative Observational Study and examined changes from baseline to 3 years in 
activities of daily living, physical activity, SF-36 mental and physical component scales 
(MCS, PCS), and menopausal symptoms.  In all adults, experimental studies published 
after 1965 were included if the sample was not restricted to participants with spasticity 
or trigeminal neuralgia and participant-reported pain was a primary or secondary 
outcome.  Pain scores were reported as Cohen’s d. 
Results:  Nine percent of post-menopausal women with MS were current smokers and 
51% reported current MHT use.  Smoking and MHT use had no effect on physical 
functioning, activities of daily living, or menopausal symptoms.  Women with early age 
at smoking initiation experienced declines in MCS (adjusted β <20 vs. ≥ 25 years: -
10.50, 95% Confidence Interval (CI) -2.1 to -18.1; adjusted β 20-24 vs. ≥ 25 years: -
8.81, 95% CI: 0.6 to -17.4), but not in PCS.  Relative to never MHT users, ever MHT 
users had higher MCS scores at year 3 compared to baseline (adjusted β: 3.0, 95% CI: 
0.4 to 5.6), but no change in PCS.   For all adults, transcutaneous electrical nerve 
stimulation (TENS; Cohen’s d: -3.34), nabixomols (Cohen’s d: -0.61), and 
dextromethorphan/quinidine (Cohen’s d: -0.22) were reported effective in reducing pain.    
Conclusions: Smoking prevention efforts should be increased for women with MS.  
Women with MS may also experience HrQOL gains with MHT, but contemporaneous 
data on MHT use is needed.  TENS may be more effective than pharmacological 
methods in reducing MS pain.   
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Chapter 1: Background 
 
Multiple sclerosis (MS) is a chronic disease that affects nearly 2.5 million people 
worldwide.1  The pathophysiology of the disease is still relatively unknown, but MS is 
physically characterized by the presence of lesions (sites of demyelinated axonal 
sheaths) in the CNS followed by partial or complete remyelination.2  Lesions have been 
linked to ‘attacks,’ or episodes of neurological symptoms which persist for at least 24 
hours.3  While the human body naturally regenerates myelin, this process may require 
months1 and subsequent attacks during the healing period may impair recovery, leading 
to more severe symptoms and functional disabilities.2     
Using magnetic resonance imaging (MRI) evidence, MS is typically diagnosed by 
the dissemination of lesions or attacks over time (at least 30 days between each onset) 
and space (multiple lesions at once throughout the CNS).3  The three major types of MS 
in order of frequency are relapsing-remitting (RRMS), primary progressive (PPMS), 
secondary progressive (SPMS).4  RRMS is characterized by clearly defined relapses 
(lesions or attacks) with full or partial recovery and a lack of disease progression.  
Similarly, PPMS consists of alternating periods of relapses and partial recovery, but 
relapses are accompanied by disease progression; this leads to steadily worsened 
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disability over the lifespan.  SPMS consists of an initial RRMS phase which later 
worsens into steadily-increased disability with few to no relapses.   
The lesions which characterize MS may present at any time in the lifespan, with 
pediatric-onset (≤ 18 years of age)2 and late-onset MS (diagnosed at age ≥ 50 years)5 
less common than adult-onset MS (diagnosed from 25 to 35 years of age).6  Similarly, 
risk factors for MS can begin as early as birth, and behaviors throughout the lifespan 
may increase future risk of MS diagnosis.  Like other autoimmune diseases, the 
strongest known risk factor for MS is family history; siblings of MS patients have 30 
times greater risk of MS than others in the general population.6  Females are also at 
greater risk for MS, as nearly two-thirds of all MS patients are women6 and women have 
an earlier age of onset than men.2, 7   
Risk factors which occur later in life are most likely to be modifiable.  These 
include environmental factors such as the latitude of residence and behavioral factors 
such as vitamin D intake and smoking.  Smoking has strong ties to MS incidence; 
studies have linked past and current smoking to earlier age of MS onset8 and increased 
pack-years to greater risk of MS.9, 10  Vitamin D insufficiency has been linked to greater 
risk of MS;11 additionally, a higher incidence of MS at higher latitudes is thought to be 
related to decreased sun exposure and decreased serum levels of vitamin D.12  In fact, 
many of the modifiable risk factors mentioned above are also related to worsened 
disease progression.  MS patients who continue to smoke after diagnosis have been 
shown to have faster rates of disability,13 while vitamin D insufficiency has been tied to 
more frequent relapses in RRMS.14 
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Because MS is a disease which originates in the central nervous system, the 
health-related quality of life for MS patients is strongly influenced by symptomology.  
Common symptoms include incontinence, pain, speech impairment, blurred vision, poor 
sleep quality, and loss of mobility.15-18  Women with MS also experience hot flashes,19, 20 
sexual dysfunction,21, 22 and vaginal dryness.23, 24  Most MS-specific therapies focus on 
slowing disease progression, but few treatments are meant for MS-specific symptomatic 
management.  Thus, it is necessary to find new ways to manage symptoms and 
improve health-related quality of life in MS patients over the lifespan.   
This dissertation assesses pain management strategies for both men and women 
with MS and symptomology and quality of life in post-menopausal women by: evaluating 
the extent to which health outcomes are worsened for post-menopausal MS patients 
who have ever smoked in comparison to MS patients who have never smoked; 
estimating the extent to which ever menopausal hormone therapy use benefits the 
health outcomes of post-menopausal women with MS in comparison to MS patients 
who have never used hormone therapy; and systematically reviewing pain management 
strategies for the reduction of non-spastic and non-trigeminal neuralgic pain in MS 
patients; 
By evaluating these outcomes in these particular subgroups, we seek to increase 
understanding of previously-published literature on pain management strategies in MS 
patients, while providing impetus for more randomized controlled trials and prospective 
longitudinal studies in the future.  Additionally, the questions answered in post-
menopausal women with MS are the first in this important subpopulation; women in the 
menopausal transition experience many of the symptoms listed above,25 indicating 
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worsened health-related quality of life for those women with MS who are also 
experiencing menopause.  Because the U.S. population is aging at an accelerated rate, 
26 this research is intended to benefit future physician decisions regarding care for aging 
patients with MS. 
 
 
  
5 
 
 
 
 
 
 
Chapter 2: Association between Smoking and Health Outcomes in 
Postmenopausal Women Living with Multiple Sclerosis 
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Abstract 
Background: Previous studies have addressed multiple sclerosis (MS) symptom 
management and improved health-related quality of life (HrQOL) through modifiable risk 
factors such as smoking.   
Objective: Evaluate the extent to which smoking is associated with worsened health 
outcomes and HrQOL for postmenopausal women with MS.  
Methods:  We identified 251 participants with MS in the Women's Health Initiative 
Observational Study.  Outcomes included changes from baseline to 3 years in in self-
reported activities of daily living, physical activity, HrQOL mental and physical 
component scales (MCS, PCS) of the SF-36, and menopausal symptoms.   
Results: Nine percent of women were current and 50% past smokers.  While never 
smokers experienced declines in physical activity, current and past smokers maintained 
their activity.  Women with early age at smoking initiation experienced declines in MCS 
(adjusted MCS β <20 vs. ≥ 25 years: -10.50, 95% Confidence Interval (CI) -2.1 to -18.1; 
adjusted MCS β 20-24 vs. ≥ 25 years: -8.81, 95% CI: 0.6 to -17.4), but not in PCS.  No 
changes in menopausal symptoms were associated with smoking status. 
Conclusion:  No effects of smoking status were observed on changes in menopausal 
symptoms.  Regardless, women with MS should be encouraged to quit smoking 
because young age at smoking initiation was associated with declining mental HrQOL 
during menopause.   
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Introduction 
Multiple sclerosis (MS) is a chronic disease of the central nervous system whose 
symptoms impact health-related quality of life (HrQOL) across the lifespan.15, 27  MS 
disproportionately affects more women than men.6  Yet, the extent to which the 
menopausal transition in women worsens MS symptoms remains largely unexplored.  
Previous studies have addressed symptom management in MS through modifiable risk 
factors such as smoking.28  It is known that 40%10, 13 of women with MS are current 
smokers, yet it is unknown how smoking affects MS outcomes post-menopause.   
In both menopausal and post-menopausal women, current smokers report 
increased odds of vasomotor symptoms, hot flashes, forgetfulness,29 and worsened 
HrQOL.30  In MS, smoking has been linked to increased incidence10 and faster MS 
progression8, 13 leading to worse health outcomes.31  More than 37 million women are 
approaching or experiencing menopause32 in a quickly aging U.S. population,26 
indicating the need for greater focus on symptom management for women with MS 
during the menopausal transition and beyond.  Using a multi-center prospective study of 
U.S. postmenopausal women, we aimed to evaluate the extent to which health 
outcomes and HrQOL are worsened for MS patients who currently smoke or previously 
smoked relative to never-smoking MS patients.  
 
Methods 
Participants 
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The Women‘s Health Initiative Observation Study (WHI-OS), sponsored by the 
National Institutes of Health and the National Heart, Lung, and Blood Institute, followed 
93,676 racially diverse women ages 50 to 79 years who were recruited from 40 clinical 
centers throughout the U.S.33  Women were eligible for participation in the WHI-OS if 
they were post-menopausal, not enrolled in other WHI clinical trials, and unlikely to 
relocate or die within 3 years. Protocols for WHI-OS were reviewed and approved by 
human subjects review committees at each participating institution.34  Analyses included 
251 WHI-OS participants with MS who completed baseline to year three assessments 
and had complete exposure information by January 2013.  Participants were considered 
diagnosed with MS if they reported ‘yes’ when answering the question, "Has a doctor 
ever told you you had MS?"   
Determination of smoking status 
Smoking status was determined from baseline self-report and was separated into 
six cigarette smoking exposure variables. During the WHI data collection period, 
participants were asked, “During your entire life, have you smoked at least 100 
cigarettes?”  Those who responded ‘yes’ were then asked, “Do you smoke cigarettes 
now?”  The responses to these questions were combined to indicate baseline smoking 
status as ever (with separate categories for current or past use) or never smoker.  
Current and past smokers were asked their ages at smoking initiation (<20 years, 20-24 
years, 25 years and older), the number of cigarettes smoked per day (<15 cigarettes per 
day, ≥ 15 cigarettes per day), and the number of years they smoked regularly (<30 
years, ≥30 years).  Past smokers were also asked their age at cessation (<40 years, 
≥40 years of age).  All categorizations were provided by the WHI.  The number of 
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smoking pack-years was calculated by multiplying the total years of smoking by the 
number of cigarettes smoked per day divided by 20,35 and categorized as <10 pack-
years, 10-29 pack-years, and ≥30 pack-years.   
Outcome ascertainment 
We evaluated changes in three types of measures: health-related quality of life, 
menopausal symptoms, and indicators of physical functioning and activity measures.  
HrQOL was measured using the RAND 36-Item Health Survey (SF-36)36 which has 
been validated in MS patients;37 for these analyses, we calculated the Mental 
Component Score (MCS) and the Physical Component Score (PCS) for each 
participant, each ranging from 0 to 100 points with 50 representing the mean score in 
the general population.  Scores below 50 indicated worse mental or physical health 
relative to the general population.   
A similar approach was used to evaluate changes in activities of daily living 
(ADL) and physical activity.  ADLs (modified from the original Katz38 index) consisted of 
four separate items regarding the participant’s ability to eat, get in and out of bed, dress, 
and/or take a bath on her own, and each item had three possible values (1=without 
help, 2=some help, and 3=completely unable).  For baseline and year 3, scores 
(ranging from 4 to 12) were summed to represent overall ADLs with a lower score 
indicating better health.  Baseline ADL scores were subtracted from year 3 ADL scores 
so that a positive change score represented a decline in ADLs.  Physical activity was 
computed from self-reported energy expenditures for recreational activities, including 
walking and other mild/moderate/strenuous activity.  These responses were scored as 
total metabolic equivalent tasks (MET) hours per week.  Previous studies in WHI 
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participants have shown calculated MET hours per week are comparable to physical 
activity diaries.39  Baseline scores were subtracted from year 3 scores such that a 
positive change score indicated an increase in physical activity. 
Based on menopause-specific symptoms adapted from the Postmenopausal 
Estrogen/Progestin Interventions symptom tool,40 we considered the following to be 
menopausal symptoms: forgetfulness, difficulty concentrating, mood swings, joint pain 
or stiffness, headaches or migraines, breast tenderness, increased or decreased 
appetite, hot flashes, night sweats, vaginal/genital irritation, and vaginal/genital dryness.  
For each symptom, participants were asked how bothersome the symptom was in the 
past four weeks (0=did not occur, 1= mild, 2=moderate, 3=severe).  Each response was 
collapsed into binary variables (0=did not occur, 1=symptom occurred (mild, moderate, 
severe)).  At baseline and year 3, a summary measure was constructed by adding the 
number of symptoms reported (scores ranged from 0 to 11).  We treated the outcome 
as a continuous variable by subtracting the baseline sum from the year 3 summary 
measure.    
Potential Covariates 
Potential confounders considered included years since menopause, alcohol use, 
body mass index (BMI), menopausal hormone therapy (MHT) use, and vitamin D intake.  
Years since menopause was calculated as the difference between youngest reported 
age when menses ceased (age when participant experienced last menstruation, 
oophorectomy, or initiated MHT) and reported age at baseline.  Baseline alcohol use 
was assessed using self-reported use and beer, wine, and liquor servings in the Food 
Frequency Questionnaire (FFQ) and categorized as never, past, and current use.  
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Baseline BMI was calculated in kg/m2 units from heights and weights measured with 
calibrated balances and stadiometers.  For these analyses, BMI was categorized 
according to the 2012 World Health Organization guidelines: BMI <18.5 kg/m2 as 
underweight, BMI between 18.5 kg/m2 and less than 25 kg/m2 as normal weight, 25 
kg/m2 to less than 30 kg/m2 as overweight, and at least 30 kg/m2 as obese.  Reported 
baseline use of MHT (unopposed estrogen and/or estrogen plus progesterone) pills or 
patches were recoded as current, past, or never use.  Baseline vitamin D insufficiency 
was defined as <800 IU by applying previously published cut points41 to data from the 
FFQ and self-reported supplement use.   
Statistical analysis 
First we reported the sociodemographic (age, race/ethnicity, education, health 
insurance status), clinical (years since menopause, BMI, alcohol use, MHT use, vitamin 
D intake), and smoking characteristics (age started smoking, cigarettes smoked per 
day, years smoked regularly, smoking pack-years, and age at smoking cessation) by 
smoking status.  Next, multivariable linear regression models were used to estimate 
associations between differences in three-year HrQOL, ADL, and physical activity 
scores and number of menopausal symptoms by baseline smoking status.  When model 
building, we examined univariate distributions of each score differences and years since 
menopause to ensure normality.  After examining missing values for determinants and 
outcomes conditional on potential confounders, we determined missing data were 
completely at random and would not produce biased estimates in these data.  
Therefore, complete case analyses were used for each model.  Multicollinearity was 
ruled out by evaluating correlations between each potential confounder (e.g. years since 
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menopause, alcohol use, BMI, MHT use, vitamin D intake).  We used an iterative 
approach to evaluate confounding.  Variables whose addition to the model resulted in ≥ 
10% change in the estimate of association were considered confounders and retained 
in the models.  We also evaluated fully adjusted models which included all potential 
confounders.  Model fit was evaluated in several ways.  We visually inspected residual 
plots to ensure residuals were spaced around zero, confirming that a linear regression 
was appropriate for these data.  Normality was confirmed by visually inspecting Q-Q 
plots for linearity.  Outliers were not found when the studentized residuals were 
examined.  We provided beta coefficients and corresponding 95% confidence intervals 
(CI) from the adjusted models.  Statistical significance was determined using an alpha 
level of 0.05. 
 
Results 
 Of the 251 women in this sample, only 6% changed smoking status from 
baseline measures to year 3.  Nearly 9% of women were current smokers and 50.2% 
were past smokers (Table 2.1).  More current smokers (65.2%) than past smokers 
(48.4%) were 59 years of age or younger at baseline.  Most women identified as non-
Hispanic White regardless of smoking status.  Of all non-Hispanic Blacks, 18.6% were 
current smokers and 61.5% were past smokers.  Regardless of smoking status, most 
women had some college or higher education levels, health insurance, and were of 
normal weight or underweight.  While 81% of never smokers reported ever alcohol use, 
83% of current and 80% of past smokers reported current alcohol use.  At least half of 
never smokers and 57% of current smokers reported MHT use while 48% of past 
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smokers reported MHT use.  All women, regardless of smoking status, had less than 
800 IU Vitamin D intake per day from food, over the counter supplements, and/or 
prescribed supplements.   
 Most women began smoking at age 25 years of age or older and most reported 
regularly smoking less than 15 cigarettes per day (Table 2.1).  Seventy-five percent of 
current smokers and 25% of past smokers reported regularly smoking for ≥ 30 years.  
When converted to pack-years, 43% of current smokers and 23% of past smokers 
smoked for 30 pack-years or more.  Most past smokers reported quitting at age 40 
years or older. 
 From baseline to year three of follow-up, greater changes in HrQOL were shown 
in the MCS rather than PCS (Table 2.2). Age at smoking initiation was associated with 
significant changes in MCS during menopause in patients with MS. Relative to women 
who began smoking at ≥ 25 years of age, women who began smoking aged less than 
20 years had lower MCS scores at year 3 compared to baseline (adjusted β: -10.50, 
95% Confidence Interval (CI): -18.9 to -2.1). PCS scores were unchanged. Similarly, 
women who began smoking at 20-24 years of age had lower MCS scores (adjusted β: -
8.81, 95% CI: -18.1 to 0.4), but no change in PCS. No differences in change in MCS 
scores were observed based on overall smoking status (current vs. past vs. never 
smoker).  Smoking pack-years were not associated with changes in PCS or MCS. 
Interestingly, past smokers who reported quitting at age 40 years or older had higher 
PCS scores (adjusted β: 3.43, 95% CI: -0.3 to 7.2) and lower MCS scores (adjusted β: -
4.45, 95% CI: -9.2 to 0.3). 
14 
 
 Table 2.3 shows the association between various definitions of smoking and 
change in ADLs and physical activity from baseline to year 3.  From baseline to year 3, 
the mean ADL change was 0.01 in never smokers and -0.02 in ever smokers.  None of 
the associations between ADL change and smoking were statistically significant.  For 
physical activity, women who reported never smoking experienced a decrease of 3.66 
MET task hours per week in physical activity, former smokers a decline of 0.60, and 
current smokers a decline of 0.10.  Relative to women who never smoked, we observed 
a slower decline in physical activity for current smokers (adjusted β: 4.15, 95% CI: -0.8 
to 9.1) and former smokers (adjusted β: 3.48, 95% CI: 0.5 to 6.4) in physical activity.   
 The five most prevalent menopausal symptoms reported at baseline included 
joint pain/stiffness (74%), forgetfulness (68%), difficulty concentrating (48%), headaches 
(45%), mood swings (42%), and vaginal dryness (31%).   Aside from joint pain (10%), 
few ranked symptoms as severe.  The least common menopausal symptom reported 
was a decrease in appetite, regardless of smoking status or time point.  Except for 
vaginal dryness, these estimates were similar at year 3.  Differences in change in 
menopausal symptoms by overall smoking status were not observed (Table 2.4).   On 
average, women who reported never smoking experienced no mean change in 
menopausal symptoms (0.01), while former smokers (0.37) and current smokers (0.48) 
reported more symptoms in year 3 relative to baseline.  Compared to women who 
began smoking at age 25 years or older, increases in the number of menopausal 
symptoms from baseline to year 3 were found for women who began smoking aged less 
than 20 years (adjusted β: 2.94, 95% CI: 0.4 to 5.5) and for women who began smoking 
between ages 20 to 24 (adjusted β: 3.27, 95% CI: 0.5 to 6.0).  Women who smoked for 
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30 pack-years or more experienced a reduction in menopausal symptoms than women 
who smoked less than 10 pack-years (adjusted β: -2.75, 95% CI: -4.7 to -0.8).   
 
Conclusions 
To our knowledge, this is the first study to estimate the associations between 
smoking status and outcomes in post-menopausal women living with MS.  Nearly half of 
all women with MS in the WHI-OS were past smokers, and most had ceased at age 40 
years or older.  Women with MS who began smoking at a young age had substantially 
worse mental HrQOL at year 3 than at baseline, indicating a decline in cognition during 
menopause for those who began smoking at age 20 years or younger. A similar trend in 
change mental HrQOL during menopause was observed for women with MS who began 
smoking between ages 20 to 24.  Change in in physical HrQOL was not associated with 
age at smoking initiation. The association between early age of smoking initiation and 
decline in mental HrQOL during menopause was not explained by current smoking 
status or by a dose-effect since greater smoking pack-years did not correspond to 
decline in MCS.  Past smokers who had ceased at age 40 years or older had improved 
physical HrQOL and worsened mental HrQOL at year 3 relative to baseline.  Little 
change was observed in ADLs regardless of smoking status, but current and former 
smokers experienced increases in physical activity from baseline to year 3 relative to 
never smokers.  The most frequently reported menopausal symptoms were joint pain or 
stiffness and forgetfulness, regardless of smoking status and time of data collection. 
Women who began smoking at younger ages (24 years or younger) experienced more 
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menopausal symptoms from baseline to year 3 relative to women who began smoking 
aged 25 years or older.  Yet women who smoked at least 30 pack-years experienced 
fewer menopausal symptoms from baseline to year 3 than women who smoked less 
than 10 pack years. 
Estimates of prevalence of smoking are much lower in this study than in previous 
reports of 40%,13 as only 9% of women reported current smoking and 59% reported that 
they had ever smoked.  This difference may be due to previous findings that WHI-OS 
participants are healthier than the general population.  Previous studies have shown 
6.3% of all WHI-OS participants at baseline were current smokers.42  Differences in 
findings may also be related to the majority of past smokers relative to current smokers.  
While previous studies have only linked ever smoking to worsened outcomes in the MS 
disease process,13 changes in HrQOL and physical functioning and activity measures 
may be strongly related to current smoking than past smoking.  For example, our 
findings of increased physical activity for current smokers also differ from previous 
findings in participants with MS and in the WHI-OS.  Previous studies report decreases 
in motor function for participants with MS within 10 minutes of smoking a cigarette,43  
Studies in the general WHI-OS population also report current smokers were less likely 
to engage in more intense physical activity over eight years of followup.44   The small 
change in physical activity for current smokers with MS but decline in never smokers 
suggests current smokers may compensate for smoking by maintaining physical 
activity. 
The results of this study show that classifying smoking status as only never, past, 
or current use may limit interpretability.  Smoking has been linked to increases in MS 
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incidence through its alterations to the blood-brain barrier45 by nitric oxide46 and is 
affected by ages at smoking initiation and smoking cessation.  Younger age at smoking 
initiation has been linked to increased risk of MS47 and worsened prognosis from 
onset.48  In our study, younger age at smoking initiation was associated with decrease in 
mental HrQOL.  Women with MS in the WHI-OS who ceased smoking at age 40 years 
or older also experienced increases in physical HrQOL but decreases in mental HrQOL 
over 3 years.  Because ever smokers are more likely to develop progressive disease 
faster than never smokers,13 smoking cessation at older ages may be too late to 
improve mental HrQOL in post-menopause. 
 The strengths of this study include the unique population and diverse outcomes 
afforded in WHI-OS data.  While the WHI was not an MS-only population, efforts were 
made during enrollment to represent the general population of post-menopausal 
women.  Additionally, while no MS-specific measures were collected in the WHI, many 
of the outcomes measured in follow-up data (e.g. SF-36 scales, ADLs) are included in 
MS-specific composite measures.  The WHI-OS also provides data not always present 
in other MS registries, such as specific questions regarding menopausal symptoms and 
their severities, frequency and duration of smoking (e.g. number of cigarettes per day, 
years of smoking before cessation), BMI calculated from physically measured weight 
and height, and vitamin D intake from supplements and food.  
Some may question the participant-reported physician diagnoses of MS used in 
the WHI.  A validation study of self-reported diagnosis of MS in the North American 
Research Committee on MS registry showed a 98.79% sensitivity of self-report when 
compared to chart review and/or physician report.49 The validation subsample 
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comprised of 59.8% women with a mean age of 54 years, indicating many of these 
women were similar in age to WHI-OS participant and were probably experiencing 
menopause or post-menopause at time of study.  While no data were available to 
ascertain time of MS diagnosis, duration of MS, type of MS, or other disability 
measures, we were comfortable with our decision to use self-reported diagnoses. 
In summary, this study evaluated the effects of smoking on HrQOL and physical 
measures in post-menopausal women with MS.  As these women were healthier than 
the general population and few were current smokers, effects were not found for all 
outcomes by all smoking frequencies or duration.  Regardless, women with MS should 
be encouraged to quit smoking.  Patterns were found pointing to an association 
between smoking initiation at younger ages and decline mental HrQOL during 
menopause.  It is known that smoking increases risk of MS, but longitudinal studies of 
age at smoking initiation and outcomes in older age for MS patients are needed.   
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Table 2.1. Baseline characteristics of postmenopausal women with multiple sclerosis 
(MS) by smoking status in the Women’s Health Initiative Observational Study. 
  
Baseline Characteristics 
Current Smoker 
(n = 23) 
Past Smoker 
(n = 126) 
Never Smoker 
(n = 102) 
 Median (Standard Deviation) 
Years since menopause 11.9 (7.2) 13.2 (8.4) 13.8 (9.4) 
 Percentages 
Age     
<50 – 59 years 65.2 48.4 46.1 
60 – 69 years 34.8 40.5 37.3 
70 – 79+ years 0 11.1 16.7 
Race/ethnicity    
Non-Hispanic White 89.5 90.0 90.5 
Non-Hispanic Black 10.5 6.4 2.4 
Hispanic 0 3.6 3.6 
Other 0 0 3.6 
Education    
≤ High school 13.0 16.0 16.8 
Some college    47.8 36.0 36.6 
≥ College graduate 39.1 48.0 46.5 
Have any health insurance 100 98.4 95.1 
Body mass index (kg/m2)    
<18.5 (underweight) 8.7 4.8 7.8 
18.5 to <25 (normal) 47.8 48.4 42.2 
25 to <30 (overweight) 26.1 26.2 33.3 
30+ (obese) 17.4 20.6 16.7 
Alcohol Use    
Never drinker 0 4.0 18.6 
Past drinker 17.4 15.9 16.7 
Current drinker 82.6 80.2 64.7 
Menopause Hormone 
Therapy    
 
Never User 34.8 34.1 35.3 
Past User 8.7 18.3 12.8 
Current User 56.5 47.6 52.0 
Vitamin D <800 IU per day 100 100 100 
Age started smoking (years)    
< 20 16.1 12.0 N/A 
20 to 24 30.1 31.0 N/A 
25 or older 53.8 57.1 N/A 
Cigarettes smoked (per day)    
< 15 52.0 55.1 N/A 
15 or more 48.0 44.9 N/A 
Years smoked regularly    
< 10 4.3 27.3 
N/A 
10 to 29 20.2 47.6 
N/A 
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30 to 49 63.4 23.7 
N/A 
50 and more 12.0 1.4 
N/A 
Pack years   
 
< 10 22.2 44.9 
N/A 
10 to 29 35.1 31.7 
N/A 
30 to 49 29.2 14.5 
N/A 
50 or more 13.6 8.9 
N/A 
Age quit smoking (years)    
< 20 N/A 1.8 N/A 
20 to 29 N/A 19.2 N/A 
30 to 39 N/A 25.2 N/A 
40 or older N/A 53.8 N/A 
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Table 2.2. Association between smoking status and change in health related quality of 
life measures over 3 years among postmenopausal women with multiple sclerosis (MS) 
in the Women’s Health Initiative Observational Study.  
1  
Adjusted for the following baseline confounders: years since menopause, alcohol use (current and past 
drinking, with referent group as never drinker), and body mass index (<18.5 kg/m as underweight, 25 
kg/m
2 
≤ BMI < 30 kg/m
2
 as overweight, and ≥ 30 kg/m
2
 as obese, with the referent group as 18.5 kg/m
2 
≤ 
BMI < 25 kg/m
2
, or normal weight). 
  
 
Δ Physical Component Score 
(3 year-baseline) 
Δ Mental Component Score 
(3 year-baseline) 
  β-Coefficient  β-Coefficient 
Exposure 
Mean Change 
(Standard 
Deviation) 
Crude 
Adjusted
1
 
(95% 
Confidence 
Interval) 
Mean 
Change 
(Standard 
Deviation) Crude 
Adjusted
1
 
(95% 
Confidence 
Interval) 
Smoking history       
    Never smokers -0.65 (8.6) Ref. Ref -0.84(12.1) Ref. Ref. 
   Ever smokers 
-1.10 (9.5) -0.45 
-0.58 
(-3.1 to 2.0) 
0.12 (11.5) 0.96 
0.24 
(-3.1 to 3.6) 
   Smoking status       
       Former smokers 
-0.74 (9.1) -0.10 
0.89 
(-1.7 to 3.4) 
-0.25 (11.2) 0.59 
-0.09 
(-3.4 to 3.2) 
             Current smokers 
-2.97 (11.7) -2.33 
-1.09 
(-5.4 to 3.2) 
2.08 (13.4) 2.91 
2.03 
(-3.7 to 7.7) 
Age started smoking (years)       
< 20 
-1.25 (9.6) 1.25 
1.52 
(-5.1 to 8.2) 
-0.93 (11.4) -10.03 
-10.50 
(-18.9 to -2.1) 
20 to 24 
-0.58 (9.0) 1.93 
2.15 
(-4.9 to 9.2) 
0.72 (11.2) -8.37 
-8.81 
(-18.1 to 0.4) 
25 or older -2.51 (12.3) Ref. Ref. 9.09 (12.4) Ref. Ref. 
Cigarettes smoked (per day)       
< 15 -1.73 (8.3) Ref. Ref. 0.71 (10.3) Ref. Ref. 
15 or more 
-0.46 (10.7) 1.27 
1.60 
(-1.5 to 4.7) 
-0.47 (12.7) -1.18 
-1.41 
(-5.5 to 2.7) 
Years smoked regularly       
< 30 -1.89 (8.8) Ref. Ref. 1.12 (10.6) Ref. Ref. 
30 or more 
-0.12 (11.1) 1.77 
1.80 
(-1.5 to 5.1) 
-1.89 (13.3) -3.01 
-2.93 
(-7.2 to 1.4) 
Number of smoking 
pack-years 
      
< 10 -1.65 (8.2) Ref. Ref. -0.05 (11.2) Ref. Ref. 
10 to 29 
-2.31 (9.0) -1.49 
-1.60 
(-4.9 to 1.7) 
2.89 (10.1) 3.61 
3.89 
(-0.6 to 8.4) 
30 or more 
1.21 (9.9) 2.03 
2.30 
(-2.8 to 7.4) 
-4.15 (13.9) -3.43 
-3.65 
(-10.3 to 3.0) 
Age quit smoking (years)       
< 40 -2.94 (8.9) Ref. Ref. 1.79 (10.8) Ref. Ref. 
40 or older 
0.46 (9.9) 3.38 
3.43 
(-0.3 to 7.2) 
-2.82 (11.9) -4.47 
-4.45 
(-9.2 to 0.3) 
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Table 2.3. Association between smoking status and change in physical functioning and 
activity scores over 3 years among postmenopausal women with multiple sclerosis (MS) 
in the Women’s Health Initiative Observational Study. 
  
1  
Adjusted for the following baseline confounders: years since menopause, alcohol use (current and past 
drinking, with referent group as never drinker), and body mass index (<18.5 kg/m as underweight, 25 
kg/m
2 
≤ BMI < 30 kg/m
2
 as overweight, and ≥ 30 kg/m
2
 as obese, with the referent group as 18.5 kg/m
2 
≤ 
BMI < 25 kg/m
2
, or normal weight). 
 Δ Activities of Daily Living 
(3 year-baseline) 
Δ Physical Activity 
(3 year-baseline) 
  β-Coefficient  β-Coefficient 
Exposure 
Mean 
Change 
(Standard 
Deviation) Crude 
Adjusted
1
 
(95% 
Confidence 
Interval) 
Mean 
Change 
(Standard 
Deviation) Crude 
Adjusted
1
 
(95% 
Confidence 
Interval) 
Smoking history       
    Never smokers 0.01 (0.5) Ref. Ref. -3.66 (12.3) Ref. Ref. 
   Ever smokers -0.02 (0.6) -0.03 
-0.06 
(-0.3 to 0.1) 
-0.53 (9.8) 3.12 
3.59 
(0.8 to 6.3) 
   Smoking status       
       Former 
smokers 
-0.01 (0.53) -0.02 
-0.05 
(0.2 to 0.1) 
-0.60 (10.2) 3.06 
3.48 
(0.5 to 6.4) 
             Current 
smokers 
-0.10 (0.62) -0.11 
-0.14 
(-0.3 to 0.1) 
-0.19 (7.0) 3.46 
4.15 
(-0.8 to 9.1) 
Age started smoking 
(years) 
      
< 20 0.0 (0.6) 0.25 
0.24 
(-0.2 to 0.6) 
-0.52 (9.3) -1.70 
-1.43 
(-9.3 to 6.4) 
20 to 24 -0.03 (0.4) 0.22 
0.22 
(-0.2 to 0.6) 
-0.89 (11.3) -2.06 
-1.75 
(-10.2 to 6.7) 
25 or older 0.25 (0.5) Ref. Ref. 1.17 (8.9) Ref. Ref. 
Cigarettes smoked (per 
day) 
      
< 15 -0.04 (0.39) Ref. Ref. 0.14 (11.0) Ref. Ref. 
15 or more 0.0 (0.7) 0.04 
0.04 
(-0.2 to 0.2) 
-1.2 (8.4) -1.33 
-1.40 
(-4.9 to 2.1) 
Years smoked regularly       
< 30 -0.08 (0.6) Ref. Ref. 0.04 (11.1) Ref. Ref. 
30 or more 0.06 (0.5) 0.14 
0.14 
(-0.1 to 0.3) 
-1.07 (6.8) -1.11 
-1.04 
(-4.8 to 2.7) 
Number of smoking 
pack-years 
      
< 10 -0.06 (0.4) Ref. Ref. -0.84 (9.6) Ref. Ref. 
10 to 29 -0.02 (0.3) -0.04 
-0.05 
(-0.2 to 0.1) 
-0.96 (11.8) 2.4 
2.65 
(-1.2 to 6.5) 
30 or more -0.27 (1.2) -0.29 
-0.30 
(-0.7 to 0.1) 
-0.40 (4.6) 1.07 
1.25 
(-4.8 to 7.3) 
Age quit smoking 
(years) 
      
< 40 0.01 (0.5) Ref. Ref. -0.60 (10.1) Ref. Ref. 
40 or older -0.10 (0.6) -0.16 
-0.16 
(-0.4 to 0.0) 
-1.09 (8.8) -0.31 
-0.48 
(-4.6 to 3.6) 
23 
 
Table 2.4. Association between smoking status and change in menopausal symptoms 
over 3 years among postmenopausal women with multiple sclerosis (MS) in the Women’s 
Health Initiative Observational Study. 
  
 
1  
Adjusted for the following baseline confounders: years since menopause, alcohol use (current and past 
drinking, with referent group as never drinker), and body mass index (<18.5 kg/m as underweight, 25 
kg/m
2 
≤ BMI < 30 kg/m
2
 as overweight, and ≥ 30 kg/m
2
 as obese, with the referent group as 18.5 kg/m
2 
≤ 
BMI < 25 kg/m
2
, or normal weight). 
 
 
Δ Menopausal Symptoms 
(3 year-baseline) 
  β-Coefficient 
Exposure 
Mean Change 
(Standard 
Deviation) Crude 
Adjusted
1
 
(95% Confidence Interval) 
Smoking history    
    Never smokers 0.01 (3.5) Ref. Ref. 
   Ever smokers 0.38 (3.5) 0.37 0.46 (-0.5 to 1.4) 
   Smoking status    
       Former smokers 0.37 (3.4) 0.35 0.43 (-0.6 to 1.4) 
              Current smokers 0.48 (4.1) 0.47 0.61(-1.0 to 2.2) 
Age started smoking (years)    
< 20 0.44 (3.7) 2.69 2.94 (0.4 to 5.5) 
20 to 24 0.70 (2.6) 2.95 3.27 (0.5 to 6.0) 
25 or older -0.16 (3.5) Ref. Ref. 
Cigarettes smoked (per day)    
< 15 0.50 (2.9) Ref. Ref. 
15 or more 0.27 (3.9) -0.23 -0.26 (-1.4 to 0.9) 
Years smoked regularly    
< 30 0.08 (3.2) Ref. Ref. 
30 or more 0.88 (4.1) 0.80 0.74 (-0.4 to 1.9) 
Number of smoking 
pack-years 
   
< 10 0.35 (3.1) Ref. Ref. 
10 to 29 0.67 (3.1) 0.0 -0.1 (-1.3 to 1.1) 
30 or more -2.13 (4.0) -2.80 -2.75 (-4.7 to -0.8) 
Age quit smoking (years)    
< 40 0.31 (3.3) Ref. Ref. 
40 or older 0.35 (3.4) 0.12 0.06 (-1.3 to 1.4) 
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Chapter 3: Association between Smoking and Health Outcomes in 
Postmenopausal Women Living with Multiple Sclerosis 
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Abstract 
Background:  Lowered estrogen levels during the menopausal transition may worsen 
quality of life for people living with multiple sclerosis (MS) by further worsening physical 
function and symptomology. 
Objective:  To evaluate the extent to which menopausal hormone treatment (MHT) 
improves health outcomes and health-related quality of life (HrQOL) for post-
menopausal patients with MS. 
Methods:  There were 256 women with MS in the Women's Health Initiative 
Observation Study with valid information at baseline and year 3.  Outcomes included 
changes from baseline to 3 years in activities of daily living, physical activity, HrQOL 
mental and physical component scales (MCS, PCS) of the SF-36, and menopausal 
symptoms.   
Results:  Fifty-one percent reported current MHT use and 14.8% reported past use.  
MHT had no effect on physical functioning, activities of daily living, or menopausal 
symptoms.  Relative to never MHT users, ever MHT users had higher MCS scores at 
year 3 compared to baseline (adjusted β: 3.0, 95% Confidence Interval: 0.4 to 5.6), but 
no change in PCS.  
Conclusion:  Women with MS may experience HrQOL gains with MHT, but its use 
must be carefully evaluated in the context of risks and benefits.  Contemporaneous data 
on MHT use is needed. 
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Introduction 
Multiple sclerosis (MS) is a progressive disease of the central nervous system 
which occurs more often in women than men.50  It is known that patient symptoms 
impact quality of life across the lifespan,16 yet it is unknown how menopause may affect 
outcomes in MS patients.  Menopause (median age of onset 52 years)25 begins a period 
of rapid decline in serum estradiol levels in women.51 Fluctuations in estrogen levels are 
linked to disease activity in women with MS.  Higher estradiol levels during pregnancy 
are associated with reduced frequency of relapses, and the precipitous decline in 
estradiol levels post-partum is associated with increased frequency of relapses.52 
Furthermore, experimental evidence indicates that estrogens have immunomodulatory 
and neuroprotective effects, 52 potentially mediating remyelination.53 Therefore, lowered 
estrogen levels during the menopausal transition might be expected to worsen MS-
related symptoms and quality of life.   
Despite the increasing incidence of MS in women54 and the millions of women 
approaching or experiencing menopause32 in the aging population,26 most studies 
concerning estrogen and MS have examined women of reproductive ages.  Thus, 
further examination of outcomes in older women with MS is needed, particularly during 
the period of natural decrease in estrogen levels in menopause and beyond.  Using a 
prospective study of American postmenopausal women, we aimed to evaluate the 
extent to which health outcomes and health-related quality of life (HrQOL) improve for 
MS patients who have ever used MHT (currently or in the past) compared to never-
using MS patients. 
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Methods 
Participants 
The Women‘s Health Initiative Observation Study (WHI-OS), sponsored by the 
National Institutes of Health and the National Heart, Lung, and Blood Institute, is a multi-
center study which followed 93,676 racially diverse women ages 50 to 79 years 
throughout the U.S.33  Eligible women were post-menopausal, not enrolled in other WHI 
clinical trials, and unlikely to relocate or die within 3 years.  Protocols for WHI-OS were 
reviewed and approved by human subjects review committees at each participating 
institution.34  Analyses included 256 WHI-OS participants with MS at baseline who 
completed year three assessments by December 2012 and completed questions 
regarding MHT.  Participants were considered diagnosed with MS if they reported ‘yes’ 
when answering the question, "Has a doctor ever told you you had MS?"   
Determination of MHT use 
Self-reported MHT use at baseline was collected in two different ways.  WHI 
participants were asked to bring in all medications currently used.  For those not 
currently using MHT, information regarding duration of previous use and type of MHT 
used (unopposed estrogen or estrogen-progesterone, in pills or patches) were 
collected.  These were categorized as MHT history (current, past, or never use), 
duration of estrogen-alone or estrogen-progesterone use (<5, 5 to 9, or 10 or more 
years), recency of estrogen-alone use (current, past <9, past 10 or more years), and 
recency of estrogen-progesterone use (current, past <5, past 5 or more years). 
Outcome ascertainment 
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We evaluated changes in menopausal symptoms, HrQOL, and indicators of 
physical functioning and activity from baseline to year three.  Using the Postmenopausal 
Estrogen/Progestin Interventions trial40 symptom tool, we considered the following to be 
menopausal symptoms: forgetfulness, difficulty concentrating, mood swings, joint pain 
or stiffness, headaches or migraines, breast tenderness, increased or decreased 
appetite, hot flashes, night sweats, vaginal/genital irritation, and vaginal/genital dryness.  
For each symptom, participants were asked how bothersome the symptom was during 
the past 4 weeks, with four possible values (0=did not occur, 1=mild, 2=moderate, and 
3=severe).  We collapsed the response categories for each symptom to a binary 
indicator variable (1=present (mild, moderate, or severe), 0=not present).  We summed 
the number of symptoms present at baseline and at year 3, separately (range 0 to 11).  
We treated the outcome as a yes/no indicator of an increase in the number of 
symptoms from baseline to year 3 (yes=increase in number of symptoms; no=decrease 
or no change).   
HrQOL was measured with the RAND 36-Item Health Survey36 using the SF-36 
scoring method, which has been validated in the MS population.37  Two summary 
scores, the Mental Component (MCS) and Physical Component Scores (PCS), were 
calculated from eight subscales (vitality, physical functioning, bodily pain, general health 
perceptions, physical role functioning, emotional role functioning, social role functioning, 
and mental health).  Scores ranged from 0 to 100 points with 50 representing the mean 
score in the general population; a score below 50 indicated worse mental or physical 
health than the general population.  Change scores from year 3 to baseline were 
computed, with a positive change score indicating an increase in HrQOL. 
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A similar approach was used to evaluate changes in activities of daily living 
(ADL) and physical activity.  ADLs recorded in the WHI (modified from the original Katz 
et al38 index) consisted of four separate items regarding the participant’s ability to eat, 
get in and out of bed, dress, and/or take a bath on her own.  Each item had three 
possible values (1=without help, 2=some help, and 3=completely unable), and scores 
were summed (ranging from 4 to 12) to represent overall ADLs with a lower score 
indicating better health.  The baseline ADL score was subtracted from the year 3 ADL 
score such that a positive change score represented a decline in ADLs.  Physical 
activity was computed from self-reported energy expenditures for recreational activities, 
including walking and other mild/moderate/strenuous activity, which are comparable to 
physical activity diaries.39  These responses were scored as total metabolic equivalent 
tasks (MET)-hours per week.  Change scores from year 3 to baseline were computed 
with a positive change score indicating an increase in physical activity. 
Covariates 
Potential confounders included years since menopause, body mass index (BMI), 
vitamin D intake, and smoking status.  Years since menopause was calculate as the 
difference between reported youngest age when menses ceased (age when participant 
experienced last menstruation, oophorectomy, or initiated MHT)55 and reported age at 
baseline.   BMI was calculated in kg/m2 units from heights and weights measured with 
calibrated balances and stadiometers.  BMI was categorized according to the 2012 
World Health Organization guidelines:56 BMI <18.5 kg/m2 as underweight, BMI between 
18.5 kg/m2 and less than 25 kg/m2 as normal weight, 25 kg/m2 to less than 30 kg/m2 as 
overweight, and at least 30 kg/m2 as obese.  Vitamin D intake was recorded using self-
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reported responses to the Food Frequency Questionnaire, which has been validated in 
the WHI cohort,57 and questions regarding supplement use.  Using previously published 
cut points,41 vitamin D insufficiency was defined as <800 IU.  Smoking status was 
determined from baseline self-report and categorized as current, past, or never smoker.   
Statistical analysis 
We reported the sociodemographic (age, race/ethnicity, education, health 
insurance status), clinical (years since menopause, vitamin D intake, BMI, alcohol use, 
smoking history), and MHT use (duration of unopposed estrogen use, recency of 
unopposed estrogen use, duration of estrogen-progesterone use, and recency of 
estrogen-progesterone use by MHT use.  Binary logistic regression models were used 
to estimate odds of increased number of menopausal symptoms from baseline to year 
3.  Confounding was evaluated in an iterative approach.  Variables whose addition to 
the model resulted in ≥ 10% change in the estimate of association were considered 
confounders and retained in the model.  We also evaluated fully adjusted models which 
included all potential confounders.  We also considered reproduction-specific covariates 
such as parity and past oral contraceptive use when modeling.  As these covariates had 
no impact on outcomes evaluated, they were excluded from adjusted models.  Odds 
ratios and 95% confidence intervals (CI) are provided for both crude and fully adjusted 
models.   
For continuous outcome variables, multivariable linear regression models were 
used to estimate associations between differences in three-year HrQOL, ADL, and 
physical activity scores by baseline MHT use.  When model building, univariate 
distributions of each score difference and years since menopause were examined to 
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ensure normality.  After examining missing values for determinants and outcomes 
conditional on potential confounders, we determined missing data were completely at 
random and would not produce biased estimates in these data.  Therefore, complete 
case analyses were used for each model.  Multicollinearity was ruled out by evaluating 
correlations between each potential confounder (e.g. years since menopause, BMI, 
vitamin D intake, and smoking status).  To evaluate confounding, we used the same 
iterative approach described above.  Model fit was evaluated in several ways.  We 
visually inspected residual plots to ensure residuals were spaced around zero, 
confirming that a linear regression was appropriate for these data.  Normality was 
confirmed by visually inspecting Q-Q plots for linearity.  Outliers were not found when 
the studentized residuals were examined.  We provided beta coefficients and 
corresponding 95% CI from the adjusted models.  Statistical significance was 
determined using an alpha level of 0.05. 
Sensitivity analysis 
In a sensitivity analysis, we evaluated the number of women who changed MHT 
use from baseline to year 3 measures.  Previous studies have shown more than 20% of 
women in the WHI-OS reported using MHT for less than 5 years at baseline.42  As MHT 
is primarily prescribed to treat vasomotor symptoms25 and these symptoms are usually 
strongest within the two years after menopause,51 we predicted some women in this 
study would change MHT use status from baseline to year 3.  Substantial changes in 
MHT use (e.g. occurred in at least 10% of women) would cause exposure 
misclassification and would potentially bias our analyses.  Therefore we evaluated the 
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number of women who reported different MHT status at year 3 and performed the 
statistical analyses listed above for this subset.   
 
Results 
 Among women with MS, 51.2% were current MHT users at baseline and 14.8% 
were past users (Table 3.1).  More than 20% of past MHT users and 7.6% of current 
users were 70 years of age or older.  Most current users identified as non-Hispanic 
White (93.8%) and 42.8% of non-Hispanic Black participants were ever users.  Nearly 
52% of current users reported their highest education level as high school diploma or 
less, relative to 35.1% of past users who reported the same.  An equivalent number of 
past or never users were underweight (past users: 10.5%, never: 10.3%) while 2.3% of 
current MHT users were underweight.  Most current and past MHT users reported 
current alcohol use, and 89.7% of current MHT users were ever smokers.  All women 
had less than 800 IU Vitamin D intake per day from food, over the counter supplements, 
and/or prescribed supplements.  Higher proportions of current MHT users had 
hysterectomies (47.3%) or oophorectomies (33.8%) relative to past users and never 
users.   
More than one half of ever MHT users had used unopposed estrogen (Table 
3.1).  Most past MHT users reported using unopposed estrogen for less than 5 years, 
while 40.5% of current users of unopposed estrogen had been using MHT for 5 or more 
years.  Forty-seven percent of past MHT users reported using estrogen and 
progesterone for less than 5 years relative to 22.1% of current MHT users reporting the 
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same.  Nearly 8% of current MHT users had switched between unopposed estrogen 
and estrogen and progesterone.   
 The most common menopausal symptom, regardless of MHT use or time point, 
was joint pain or stiffness (Table 3.2).  Overall, a similar number of women had 
increases in symptoms from baseline to year 3, regardless of MHT use.  In particular, 
40.5% of current MHT users reported joint pain or stiffness at year 3 relative to 29% at 
baseline.  After adjusting for years since menopause, smoking status, and BMI, the 
odds ratios for increased symptoms at year 3 was 0.81 for current users (95% 
Confidence Interval (CI): 0.43 to 1.51) and 0.68 for past users (95% CI: 0.28 to 1.69) 
when compared to never users. 
 Table 3.3 shows the association between MHT use and change in HrQOL from 
baseline to year 3 in subjects with MS.  Relative to never MHT users, ever MHT users 
had a non-statistically significant increase in MCS scores at year 3 compared to 
baseline (adjusted β: 3.0, 95% CI: -0.3 to 6.3), but no change in PCS.  Never users 
experienced an average 1.96 point decline (standard deviation: 10.4) in MCS from 
baseline to year 3, whereas women with MS who ever used MHT on average 
experienced a 0.63 increase in MCS (standard deviation: 12.3).  For women who had 
ever used unopposed estrogen, greater increases in HrQOL were shown in MCS rather 
than PCS.  Women who used unopposed estrogen for less than 5 years had little 
change in PCS but higher MCS scores at year 3 compared to baseline (adjusted β: 
3.09, 95% CI: -2.0 to 8.2), although not statistically significant.  Past users tended to 
have higher MCS scores at year 3 compared to baseline compared to never users (<10 
years: adjusted β: 3.14, 95% CI: -3.7 to 10.0; 10+ years: adjusted β: 4.18, 95% CI: -3.5 
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to 11.8).  Interestingly, the effect of MHT use on MCS was not observed for estrogen-
progesterone users. For women with MS who had ever used estrogen and 
progesterone no changes in MCS scores were apparent.  PCS scores were lower at 
year 3 than at baseline for women who had used estrogen and progesterone for less 
than 5 years (adjusted β: -3.6, 95% CI: -7.5 to -0.3) and past users who ceased 5+ 
years ago (adjusted β: -6.0, 95% CI: -11.3 to -0.7).   
 The association between MHT use and change in ADLs and physical activity 
from baseline to year 3 are shown in Table 3.4.  None of the associations between ADL 
change and MHT use were statistically significant.  Little change in ADL scores were 
observed from baseline to 3 years.  The mean ADL change was -0.02 in never MHT 
users and -0.01 in ever users.  For physical activity, 45.5% of women with MS had 
greater than 8 MET-hours/week of physical activity at baseline.  The overall patterns 
observed indicated that women decreased their activity on average ~2 MET task 
hours/week from baseline to year 3.  Women who used unopposed estrogen for 10 or 
more years maintained their activity levels resulting in a net increase of 2.57 MET task 
hours/week from baseline to year 3, compared to never users.  None of the associations 
between MHT and changes in physical activity were statistically significant. 
 In our sensitivity analyses, we found 39 women (15.2% of the sample) had 
changed MHT status at year 3 assessments (Table 3.5).  Most of these women were 
never or past users at baseline who began using MHT by year 3 (76.9%), while only 9 
women who reported using MHT at baseline stopped at year 3.  Similar to all women 
included in our sample, this subset was also mostly non-Hispanic White, overweight or 
obese, and current alcohol users.  Most baseline MHT users stopped using unopposed 
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estrogen after less than 9 years duration.  As in the general sample, the most common 
menopausal symptoms were joint pain or stiffness and forgetfulness (Table 3.6).  Unlike 
the general sample, at least half of all women who had changed MHT status 
experienced increases in symptoms by year 3.  Non-significant associations were found 
for increased symptoms at year 3 by baseline MHT status.   
 Directions of associations between baseline MHT status and MCS and PCS for 
women who changed MHT use by year 3 were similar to those found in the total 
sample, but greater in magnitude (Table 3.7).  Ever users at baseline experienced non-
statistically significant decreases in PCS (adjusted β: -3.39, 95% CI: -10.8 to 4.1) and 
increases in MCS (adjusted β: 3.0, 95% CI: -0.3 to 6.3) at year 3, relative to never 
users.  Never users at baseline experienced an average 2.56 point decline (standard 
deviation: 8.5) in MCS from baseline to year 3, while ever users at baseline on average 
experienced a 3.52 increase in MCS (standard deviation: 16.2).  For women who had 
ever used unopposed estrogen at baseline, greater increases in HrQOL were shown in 
MCS rather than PCS.  Women who used unopposed estrogen for less than 9 years 
had little change in PCS but higher MCS scores at year 3 compared to baseline 
(adjusted β: 12.73, 95% CI: -0.8 to 26.3), although not statistically significant.  Past 
users tended to have higher MCS scores at year 3 compared to baseline compared to 
never users (adjusted β: 11.12, 95% CI: -3.8 to 26.0).  For women with MS who had 
ever used estrogen and progesterone, decreases in MCS scores were greater in 
magnitude than in the total sample.  Women who had ever used estrogen-progesterone 
at baseline experienced non-significant increases in PCS and decreases in MCS scores 
at year 3 compared to baseline.  Past users who stopped using MHT less than 5 years 
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before baseline had significant decreases in MCS at year 3 (adjusted β: -18.75, 95% CI: 
-33.8 to -3.7) compared to never users at baseline.   
 As in the total sample, no significant associations were found between changes 
in limitations due to ADLs and MHT use at baseline for women who changed their MHT 
status at year 3 (Table 3.8).  Additionally, none of the associations between MHT and 
changes in physical activity were statistically significant.  Relative to never users, ever 
MHT users at baseline maintained their physical activity at year 3.  Current users of 
unopposed estrogen at baseline increased physical activity at year 3 (adjusted β: 6.16, 
95% CI: -7.8 to 19.9) relative to never users, while current users of estrogen-
progesterone at baseline experienced no changes.  Women who had used estrogen-
progesterone for less than 5 years at baseline had fewer decreases in physical activity 
relative to never users than women who had used estrogen-progesterone for at least 10 
years.  Yet women who had used unopposed estrogen for at least 10 years at baseline 
had increases in physical activity at year 3 relative to never users (adjusted β: 7.84, 
95% CI: -8.0 to 23.7), while women who had used unopposed estrogen for less than 10 
years at baseline decreased physical activity at year 3 (adjusted β: -6.69, 95% CI: -18.3 
to 4.9).   
Conclusions 
To our knowledge, this is the first study to estimate the associations between 
MHT and outcomes in women living with MS.  MHT use was common in women with 
MS.  In our study, 51% percent reported current use and 14.8% past use.  This is 
consistent with previous reports of the general WHI population report 45.5% current 
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use.42  The extent to which these estimates would be consistent with a contemporary 
cohort is unclear as the 2002 results of the WHI clinical trial in estrogen-progestin in 
healthy women58 resulted in nationally reduced MHT use.59  In our study, unopposed 
estrogen was the most cited choice for managing menopausal symptoms.  Additionally, 
the women in our study who had stopped using MHT by enrollment in the WHI-OS but 
resumed use at year 3 experienced more menopausal symptoms and worse mental 
HrQOL than the total sample, indicating that women with MS may be seeking MHT for 
relief of symptoms. 
The findings regarding HrQOL and MHT among women with MS are intriguing.  
Overall, women with MS reporting MHT use had less declines in mental HrQOL 
measures (MCS) compared to never users of MHT, suggesting a beneficial effect of 
estrogen use on mental health in women with MS during menopause.  When evaluating 
this finding by type of MHT, we found that for women who had used unopposed 
estrogen, greater increases were found in MCS scores than in PCS scores over three 
years of follow-up.  Yet for women who had used estrogen and progesterone, greater 
decreases in PCS scores than in MCS scores were found.  Greater changes in MCS 
scores are consistent with recent experimental autoimmune encephalomyelitis models, 
which suggest that estrogen is protective for synaptic transmission and may improve 
memory and cognition in people living with MS.60  Our findings of greater decreases in 
PCS than MCS for estrogen-progesterone users differ from other studies in 
postmenopausal women with intact uteri.  A study in women61 who had used estrogen-
progesterone reported non-significant increases in PCS subscales over 9 months, all of 
which were below the population norms for Canadian women aged 45 to 54 years.  
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Additionally, estrogen-progesterone has been shown to have protective effects62 in 
postmenopausal women with cognitive complaints.  As most women in our study were 
aged 69 years or younger but had used estrogen-progesterone for up to nine years, it is 
possible that estrogen-progesterone was not initiated at the youngest appropriate age to 
effectively improve mental and physical HrQOL or physical functioning. 
Our study found no overall association between MHT and measures of physical 
functioning and physical activity.  This is consistent with reports from the WHI 
randomized trials which also demonstrated no association with self-reported outcomes63, 
64 and trials using change in performance-based measures of physical function.65, 66  At 
baseline, 45.5% of women with MS had greater than 8 MET-hours/week of physical 
activity.  This is consistent with previous reports of 55.5% of all women in the WHI-OS 
with similar levels of physical activity.42   
We found no overall association between MHT and changes in menopausal 
symptoms.  This is inconsistent with the state of the science report on management of 
menopausal symptoms suggests that there is a beneficial effect on some common 
symptoms.25  The discrepancy between our study and the literature may be owing to 
several reasons.  First, because of the limited number of women with MS, we could not 
evaluate each individual symptom.  Instead we used a composite score which may have 
diluted our ability to show benefit of MHT.  Second, our data showed a beneficial effect, 
but we may not have had sufficient power to demonstrate statistical significance.  Third, 
in women with MS, the most frequently reported menopausal symptoms were joint pain 
or stiffness, regardless of MHT use and time of data collection.  This is consistent with 
previous findings from the WHI clinical trials and consensus statements which show 
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frequent reports of joint pain during menopause, but no clear association between 
menopausal status and joint pain.25, 67  Fourth, women with MS may experience fewer 
symptoms which are most amenable to MHT intervention.  While previous reports of 
WHI indicated that vaginal dryness was reported in 27.0% and vaginal irritation or 
itching in 18.6% of all women,68 women with MS had lower reports of these symptoms at 
baseline.   
 Strengths of this study include the study population and outcomes evaluated.  
The WHI-OS focused on enrollment so that the study participants would represent the 
general population of postmenopausal women, particularly those of different 
races/ethnicities.  Our study population captured women in a more generalizable 
community setting, which offers an advantage to other MS studies conducted in clinical 
settings.  Indeed, the sample size available for this study (n=256) exceeds most single-
center studies of patients with MS.  To our knowledge, only one study20 attempted to 
capture menopausal symptoms experienced by women living with MS.  This cross-
sectional study was conducted over twenty years ago and included only 19 post-
menopausal women.  By evaluating the associations between MHT use and 
menopausal symptoms for women with MS in longitudinal WHI data, we were able to 
use menopause-specific measures and validated tools for physical functioning, physical 
activity, and HrQOL provided by the WHI.   
The WHI, however, captured diagnosis of MS using participant-reported 
physician diagnoses of MS.  No data were available in the WHI-OS to ascertain time of 
MS diagnosis, duration of MS, type of MS, or other MS-specific disability measures.  
While the WHI did not collect MS-specific measures, MS registries also rely on self-
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reported symptoms and physical function69 and validation studies have shown self-
report is an accurate representation of the MS disease experience.70  In a sample of MS 
patients (59.8% female with a mean age of 53.49 years), self-reported diagnoses was 
98.79% sensitive when compared to chart review and/or physician report.49  
Additionally, while prevalence of MHT use in the WHI was higher than use in 
postmenopausal women today,59 the 3-year analysis period in this study reflects current 
guidelines for MHT use and is relevant in women living with MS today.71 
In summary, this study evaluated the effects of MHT use on HrQOL and physical 
measures in post-menopausal women with MS.  Consistent with previous research, we 
found no overall effect of MHT on physical functioning and activity.  However, our 
findings show MHT may positively impact mental HrQOL in women with MS, and those 
women who are experiencing worse symptoms may seek relief with MHT.25  While more 
longitudinal assessments of frequency and duration of MHT use in MS patients are 
needed, previous surveys72 have shown nearly 70% of post-menopausal women with 
MS do not use MHT for symptom relief.  Healthcare professionals should consider 
available MHT regimens in the context of efficacy and risk of adverse events when 
treating symptoms during menopause and post-menopause. 
41 
 
Table 3.1. Baseline characteristics of postmenopausal women with multiple sclerosis 
(MS) by MHT use in the Women’s Health Initiative Observational Study. 
  
Baseline Characteristics 
Current MHT user 
(n = 131) 
Past MHT user 
(n = 38) 
Never MHT user 
(n = 87) 
 Median (Standard Deviation) 
Years since menopause 12.4 (8.3) 16.1 (10.6) 13.6 (8.2) 
 Percentages 
Age     
<50 – 59 years 56.5 47.4 37.9 
60 – 69 years 35.9 26.3 48.3 
70 – 79+ years 7.6 26.3 13.8 
Race/ethnicity    
Non-Hispanic White 93.8 89.7 85.3 
Non-Hispanic Black 1.8 6.9 9.3 
Hispanic 2.7 3.5 4.0 
Other 1.8 0.0 1.8 
Education    
≤ High school 51.5 35.1 43.7 
Some college    36.2 48.7 35.6 
≥ College graduate 12.3 16.2 16.2 
Have any health insurance 98.5 100 94.2 
Body mass index (kg/m
2
)    
<18.5 (underweight) 2.3 10.5 10.3 
18.5 to <25 (normal) 51.9 44.7 37.9 
25 to <30 (overweight) 29.0 26.3 29.9 
30+ (obese) 16.8 18.4 21.8 
Alcohol Use    
Never drinker 8.4 10.5 10.3 
Past drinker 15.3 21.1 16.1 
Current drinker 76.3 68.4 73.6 
Smoking History    
Never  42.1 34.2 41.4 
Past  47.6 60.5 49.4 
Current  10.3 5.3 9.2 
Vitamin D intake <800 (μg/day) 100 100 100 
Ever Hysterectomy 47.3 36.8 25.3 
Ever Oophorectomy
1
 33.8 23.7 25.3 
Ever Oral Contraceptive Use 57.3 31.6 44.8 
Gravidity    
1 to 4 pregnancies 69.5 78.9 58.6 
5+ pregnancies 18.0 13.2 27.6 
Parity    
Never pregnant/term pregnancy 13.7 10.5 18.4 
1 to 3 term pregnancies 71.8 65.8 58.6 
4+ term pregnancies 14.5 23.7 23.0 
MHT type used    
Ever unopposed estrogen 58.8 55.3 N/A 
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1
 Includes the removal of one or both ovaries. 
  
Ever estrogen-plus-progesterone 41.2 44.7 N/A 
Unopposed estrogen duration    
< 5 years 18.3 34.2 N/A 
5-9 years 13.0 7.9 N/A 
10+years 27.5 13.2 N/A 
Recency of estrogen-alone use    
Current 51.2 N/A N/A 
Past<9 years 5.3 23.7 N/A 
Past 10+ years ago 2.3 31.6 N/A 
 
Estrogen-plus-progesterone duration 
   
< 5 years 22.1 47.4 N/A 
5-9 years 20.6 5.3 N/A 
10+years 13.7 2.6 N/A 
Recency of estrogen-plus-progesterone 
   
Current 48.9 N/A N/A 
Past < 5 years 2.3 36.8 N/A 
Past 5+ years 5.3 18.4 N/A 
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Table 3.2. Association between MHT use and menopausal symptoms at 3 year followup 
among post-menopausal women with MS 
 
1 
Here, the outcome evaluated is a yes/no indicator of an increase in the number of symptoms from 
baseline to year 3 (yes = an increase in the number of symptoms; no = a decrease or no change), with no 
as the referent group.   
2  
Adjusted for the following baseline confounders: years since menopause, smoking status, alcohol use, 
and body mass index (<18.5 kg/m as underweight, 25 kg/m
2 
≤ BMI < 30 kg/m
2
 as overweight, and ≥ 30 
kg/m
2
 as obese, with the referent group as 18.5 kg/m
2 
≤ BMI < 25 kg/m
2
, or normal weight). 
  
Menopausal Symptoms 
Current MHT user 
(n = 131) 
Past MHT user 
(n = 38) 
Never MHT user 
(n = 87) 
Baseline Year 3 Baseline Year 3 Baseline Year 3 
 Percentages 
Forgetfulness 14.5 14.5 21.1 21.1 17.2 20.7 
Difficulty concentrating 10.7 9.9 13.2 13.2 9.2 11.5 
Mood swings 9.2 7.6 10.5 10.5 11.5 14.9 
Joint pain or stiffness 29.0 40.5 34.2 34.2 29.9 33.3 
Headaches or migraines 13.0 10.7 10.5 13.2 12.6 13.8 
Breast tenderness 5.3 3.1 2.6 7.9 1.2 2.3 
Increased appetite 8.4 7.6 13.2 10.5 10.3 11.5 
Decrease appetite 2.3 2.3 0 0 4.6 1.2 
Hot flashes 5.3 6.1 7.9 10.5 9.2 2.3 
Night sweats 8.4 8.4 10.5 7.9 9.2 9.2 
Vaginal/genital irritation 4.6 5.3 2.6 2.6 1.2 2.3 
Vaginal/genital dryness 3.8 7.6 10.5 18.4 9.2 6.9 
Average number of 
symptoms  
(Standard Deviation) 
1.15 
(1.41) 
1.24 (1.64) 1.37 (1.79) 
1.50 
(1.66) 
1.25 
(1.59) 
1.30 
(1.64) 
Increase in symptoms 
 
 
24.4 
 
 
23.7 
 
 
27.6 
 
Crude OR
1
 (95% CI) 
0.85 (0.46 to 1.57) 0.82 (0.34 to 1.97) 
Reference 
Adjusted
2
 OR (95% CI) 
0.81 (0.43 to 1.51) 0.68 (0.28 to 1.69) 
Reference 
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Table 3.3. Association between MHT status and change in health-related quality of life 
measures over 3 years among postmenopausal women with multiple sclerosis (MS) in 
the Women’s Health Initiative Observational Study.  
1  
Adjusted for the following baseline confounders: years since menopause, alcohol use (current and past 
drinking, with referent group as never drinker), and body mass index (<18.5 kg/m as underweight, 25 
kg/m
2 
≤ BMI < 30 kg/m
2
 as overweight, and ≥ 30 kg/m
2
 as obese, with the referent group as 18.5 kg/m
2 
≤ 
BMI < 25 kg/m
2
, or normal weight).  
 Δ Physical Component Score 
(3 year-baseline) 
Δ Mental Health Component Score 
(3 year-baseline) 
  β-Coefficient  β-Coefficient 
Exposure 
Mean 
Change 
(Standard 
Deviation) 
Crude 
 
Adjusted
1
 
(95% 
Confidence 
Interval) 
Mean Change 
(Standard 
Deviation) 
Crude 
 
Adjusted
1
 
(95% 
Confidence 
Interval) 
MHT history       
    Never  -0.06 (9.2)   -1.96 (10.4)   
   Ever  -1.36 (9.0) 1.30 
-1.41  
(-4.0 to 1.1) 
0.63 (12.3) 2.59  
3.00 
(-0.3 to 6.3) 
Unopposed 
estrogen duration 
      
< 5 years -0.83 (10.9) 0.83 
0.17 
(-3.8 to 4.1) 
2.71 (12.5) 2.24 
3.09 
(-2.0 to 8.2) 
5-9 years -0.33 (8.8) 1.33 
0.33  
(-4.8 to 5.4) 
0.59 (12.9) 0.12 
1.09 
(-5.6 to 7.8) 
10+years -1.77 (9.2) -0.11 
-1.15  
(-5.3 to 3.0) 
-0.95 (11.5) -1.42 
-0.36 
(-5.8 to 5.1) 
Recency of 
unopposed 
estrogen use 
      
Current -1.00 (9.7) 0.66 
-0.04 
(-3.6 to 3.5) 
-0.10 (13.3) -0.57 
0.55 
(-4.0 to 5.1) 
Past <10 
years 
-2.3 (12.8) -0.64 
-0.76 
(-6.1 to 4.6) 
3.04 (7.5) 2.57 
3.14 
(-3.7 to 10.0) 
Past 10+ 
years ago 
-0.53 (6.2) 1.13 
-0.76 
(-6.6 to 5.1) 
1.78 (11.0) 1.31 
4.18 
(-3.5 to 11.8) 
Estrogen-plus-
progesterone 
duration 
      
< 5 years -4.44 (9.9) -4.16 
-3.60 
(-7.5 to 0.3) 
0.90 (10.5) 0.21 
-1.07 
(-6.2 to 4.0) 
5-9 years 0.05 (7.2) 0.34 
1.18 
(-3.1 to 5.5) 
-0.25 (10.7) -0.94 
-2.50 
(-8.2 to 3.2) 
10+years -0.93 (9.4) -0.64 
-0.04 
(-4.9 to 4.9) 
1.24 (15.8) 0.54 
0.06 
(-6.5 to 6.4) 
Recency of 
estrogen-plus-
progesterone use 
      
Current -0.77 (9.3) -0.48 
0.52 
(-3.0 to 4.1) 
0.49 (11.4) -0.20 
-1.49 
(-6.2 to 3.2) 
Past < 5 
years 
-3.2 (5.7) -2.95 
-1.80 
(-7.1 to 3.5) 
-0.11 (13.5) -0.80 
-2.24 
(-9.3 to 4.8) 
Past 5+ years -7.03 (10.2) -6.74 
-6.00 
(-11.3 to -0.7) 
1.70 (10.3) 1.01 
0.29 
(-6.8 to 7.4) 
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Table 3.4: Association between MHT status and change in physical functioning and 
activity scores over 3 years among postmenopausal women with multiple sclerosis (MS) 
in the Women’s Health Initiative Observational Study.  
1  
Adjusted for the following baseline confounders: years since menopause, alcohol use (current and past 
drinking, with referent group as never drinker), and body mass index (<18.5 kg/m as underweight, 25 
kg/m
2 
≤ BMI < 30 kg/m
2
 as overweight, and ≥ 30 kg/m
2
 as obese, with the referent group as 18.5 kg/m
2 
≤ 
BMI < 25 kg/m
2
, or normal weight). 
 Δ Activities of Daily Living 
(3 year-baseline) 
Δ Physical Activity 
(3 year-baseline) 
  β-Coefficient  β-Coefficient 
Exposure 
Mean 
Change 
(Standard 
Deviation) 
Crud
e 
 
Adjusted
1
 
(95% 
Confidence 
Interval) 
Mean 
Change 
(Standard 
Deviation) 
Crude 
 
Adjusted
1
 
(95% Confidence 
Interval) 
MHT history       
    Never  -0.02 (0.51)   -1.76 (11.2)   
   Ever  -0.01 (0.58) 0.01 
-0.01 
(-0.2 to 0.2) 
-1.84 (10.8) -0.08 
0.51 
(-2.4 to 3.5) 
Unopposed 
estrogen duration 
      
< 5 years -0.03 (0.5) -0.03 
0.05 
(-0.1 to 0.2) 
-3.22 (11.6) -0.82 
-0.90 
(-5.4 to 3.6) 
5-9 years 0.00 (0.3) 0.00 
0.01 
(-0.2 to 0.2) 
-1.09 (15.6) 1.31 
1.61 
(-4.1 to 7.3) 
10+years -0.03 (0.3) -0.03 
0.00 
(-0.2 to 0.2) 
0.01 (10.0) 2.42 
2.57 
(-2.3 to 7.5) 
Recency of 
unopposed 
estrogen use 
      
Current -0.06 (0.3) -0.06 
0.00 
(-0.2 to 0.2) 
-0.52 (12.7) 1.89 
1.85 
(-2.1 to 5.8) 
Past<9 years 0.06 (0.3) 0.06 
0.08 
(-0.3 to 0.5) 
-6.23 (13.0) -3.83 
-3.61 
(-9.7 to 2.5) 
Past 10+ 
years ago 
0.07 (0.5) 0.07 
0.12 
(-0.3 to 0.5) 
-0.42 (2.4) 1.99 
1.95 
(-4.7 to 8.6) 
Estrogen-plus-
progesterone 
duration 
      
< 5 years 0.05 (0.6) 0.07 
0.04 
(-0.2 to 0.2) 
-2.26 (8.9) -1.79 
-1.46 
(-5.8 to 2.9) 
5-9 years 0.0 (0.5) 0.03 
-0.03 
(-0.2 to 0.1) 
-3.81 (9.7) -3.34 
-3.17 
(-8.3 to 1.9) 
10+years -0.11 (1.1) -0.08 
-0.21 
(-0.4 to 0.0) 
-3.24 (8.6) -2.78 
-2.13 
(-7.8 to 3.6) 
Recency of 
estrogen-plus-
progesterone use 
      
Current -0.03 (0.7) -0.01 
-0.07 
(-0.6 to 0.1) 
-3.67 (10.2) 
-3.2 
(1.9) 
-2.9 
(-6.8 to 1.0) 
Past < 5 
years 
0.19 (0.8) 0.22 
0.16 
(-0.2 to 0.6) 
0.64 (4.1) 
1.1 
(2.9) 
1.5 
(-4.4 to 7.4) 
Past 5+ years -0.07 (0.3) -0.04 
-0.10 
(-0.5 to 0.3) 
-3.94 (7.1) 
-3.5 
(3.2) 
-3.2 
(-9.5 to 3.1) 
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Table 3.5. Baseline characteristics of postmenopausal women with multiple sclerosis 
(MS) who changed MHT use status by year 3 in the Women’s Health Initiative 
Observational Study.  
Baseline Characteristics 
Baseline: Current 
MHT user 
(n = 9) 
Baseline: Past 
MHT user 
(n = 13) 
Baseline: Never 
MHT user 
(n = 17) 
 Median (Standard Deviation) 
Years since menopause 11.8 (9.5) 11.0 (7.8) 12.3 (12.1) 
 Percentages 
Age     
<50 – 59 years 66.7 46.2 64.7 
60 – 69 years 22.2 46.2 17.7 
70 – 79+ years 11.1 7.7 17.7 
Non-Hispanic White 100.0 81.8 85.7 
Education    
≤ Some college 33.3 50.0 58.8 
≥ College graduate 66.7 50.0 41.2 
Have any health insurance 100.0 100.0 100.0 
Body mass index (kg/m
2
)    
<25 (underweight to normal) 44.4 46.2 35.3 
25 to <30 (overweight) 44.4 23.1 53.0 
30+ (obese) 11.1 30.8 11.8 
Alcohol Use    
Never drinker 0 15.4 17.7 
Past drinker 11.1 7.7 11.8 
Current drinker 88.9 76.9 70.6 
Smoking History    
Never  37.5 23.1 52.9 
Ever (Current or Past)  62.5 76.9 47.1 
Vitamin D intake <800 (μg/day) 100.0 100.0 100.0 
Ever Hysterectomy 55.6 15.4 23.5 
Ever Oophorectomy
1
 44.4 7.7 29.4 
Ever Oral Contraceptive Use 44.4 30.8 47.1 
Gravidity    
1 to 4 pregnancies 77.8 69.2 58.8 
5+ pregnancies 22.2 15.4 35.3 
Parity    
Never pregnant/term pregnancy 33.3 15.4 5.9 
1 to 3 term pregnancies 44.4 53.8 52.9 
4+ term pregnancies 22.2 30.8 41.2 
MHT type used    
Ever unopposed estrogen 66.7 23.1 N/A 
Ever estrogen-plus-progesterone 33.3 76.9 N/A 
Unopposed estrogen duration    
<10 years 44.4 15.4 N/A 
10+years 22.2 7.7 N/A 
Recency of estrogen-alone use    
Current 55.6 N/A N/A 
Past 11.1 23.1 N/A 
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1
 Includes the removal of one or both ovaries. 
  
 
Estrogen-plus-progesterone duration 
   
< 5 years 33.3 69.2 N/A 
5+ years 11.1 7.7 N/A 
Recency of estrogen-plus-progesterone 
   
Current 44.4 N/A N/A 
Past  0.0 76.9 N/A 
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Table 3.6. Association between MHT use and menopausal symptoms at 3 year followup 
among post-menopausal women with MS who changed MHT use status by year 3. 
 
1 
Here, the outcome evaluated is a yes/no indicator of an increase in the number of symptoms from 
baseline to year 3 (yes = an increase in the number of symptoms; no = a decrease or no change), with no 
as the referent group.   
2  
Adjusted for the following baseline confounders: years since menopause, smoking status, alcohol use, 
and body mass index (<18.5 kg/m as underweight, 25 kg/m
2 
≤ BMI < 30 kg/m
2
 as overweight, and ≥ 30 
kg/m
2
 as obese, with the referent group as 18.5 kg/m
2 
≤ BMI < 25 kg/m
2
, or normal weight). 
  
Menopausal Symptoms 
Baseline: Current 
MHT user 
(n = 9) 
Baseline: Past MHT 
user 
(n = 13) 
Baseline: Never MHT 
user 
(n = 17) 
Baseline Year 3 Baseline Year 3 Baseline Year 3 
 Percentages 
Forgetfulness 11.1 11.1 30.8 23.1 35.3 35.3 
Difficulty concentrating 11.1 0.0 0.0 23.1 5.9 23.5 
Mood swings 0.0 0.0 23.1 23.1 5.9 11.8 
Joint pain or stiffness 11.1 22.2 38.5 46.2 41.2 35.3 
Headaches or migraines 11.1 11.1 23.1 15.4 11.8 23.5 
Breast tenderness 0.0 0.0 7.7 15.4 0.0 0.0 
Increased appetite 0.0 0.0 23.1 7.7 23.5 17.7 
Decrease appetite 0.0 0.0 0.0 0.0 0.0 0.0 
Hot flashes 11.1 22.2 15.4 15.4 11.8 5.9 
Night sweats 0.0 11.1 15.4 7.7 17.7 11.8 
Vaginal/genital irritation 0.0 0.0 7.7 0.0 0.0 0.0 
Vaginal/genital dryness 0.0 0.0 7.7 7.7 0.0 11.8 
Average number of 
symptoms  
(Standard Deviation) 
0.56 
(1.3) 
0.78 
(1.1) 
1.92 
(2.4) 
1.85 
(2.0) 
1.53 
(1.3) 
1.76 
(1.8) 
Increase in symptoms  50.0  53.9  35.3 
Crude OR
1
 (95% CI) 1.20 (0.21 to 6.80) 0.44 (0.07 to 2.72) Reference 
Adjusted
2
 OR (95% CI) 1.02 (0.13 to 8.04) 0.37 (0.05 to 2.64) Reference 
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Table 3.7. Association between MHT status and change in health-related quality of life 
measures over 3 years among postmenopausal women with multiple sclerosis (MS) who 
changed MHT use status by year 3. 
1  
Adjusted for the following baseline confounders: years since menopause, alcohol use (current and past 
drinking, with referent group as never drinker), and body mass index (<18.5 kg/m as underweight, 25 
kg/m
2 
≤ BMI < 30 kg/m
2
 as overweight, and ≥ 30 kg/m
2
 as obese, with the referent group as 18.5 kg/m
2 
≤ 
BMI < 25 kg/m
2
, or normal weight).  
 Δ Physical Component Score 
(3 year-baseline) 
Δ Mental Health Component Score 
(3 year-baseline) 
  β-Coefficient  β-Coefficient 
Exposure 
7.ean 
Change 
(Standard 
Deviation) 
Crude 
 
Adjusted
1
 
(95% Confidence 
Interval) 
Mean Change 
(Standard 
Deviation) 
Crude 
 
Adjusted
1
 
(95% Confidence 
Interval) 
MHT history       
    Never  -0.11 (7.6)   -2.56 (8.5)   
   Ever  -2.56 (8.5) -2.45 
-3.39 
(-10.8 to 4.1) 
3.52 (16.2) 4.21 
3.89  
(-6.3 to 14.1) 
Unopposed 
estrogen duration 
      
< 10 years -1.38 (9.5) 0.88 
-0.62 
(-12.6 to 11.3) 
10.21 (14.6) 11.29 
12.73 
 (-0.8 to 26.3) 
10+years -5.16 (18.0) -2.9 
0.94 
(-12.8 to 14.7) 
9.92 (19.2) 11.00 
1.45 
(-14.0 to 16.9) 
Recency of 
unopposed 
estrogen use 
      
Current -7.64 (15.4) -5.39 
-6.87 
(-18.8 to 5.1) 
-0.10 (17.5) 13.31 
15.36 
(-0.5 to 31.2) 
Past  3.20 (3.3) 5.46 
6.01 
(-5.2 to 17.2) 
7.22 (14.4) 8.31 
11.12 
(-3.8 to 26.0) 
Estrogen-plus-
progesterone 
duration 
      
< 5 years -1.80 (5.8) 2.84 
1.58 
(-9.6 to 12.8) 
-0.05 (16.9) -11.73 
-9.18 
(-23.3 to 4.9) 
5-9 years -2.40 (2.4) 2.24 
3.90 
(-16.1 to 23.9) 
-7.73 (7.7) -19.42 
-22.01 
(-3.5 to 47.5) 
10+years 2.93 (2.9) 2.84 
5.82 
(-15.5 to 27.2) 
-2.21 (2.2) -13.90 
-12.94 
(-40.2 to 14.3) 
Recency of 
estrogen-plus-
progesterone use 
      
Current 4.32 (8.1) 8.96 
7.96 
(-7.1 to 23.1) 
1.26 (12.9) -10.42 
-3.99 
(-22.4 to 14.4) 
Past < 5 
years 
-2.80 (3.6) 1.84 
1.09 
 (-11.3 to 13.4) 
-5.70 (18.7) -17.39 
-18.75 
(-33.8 to -3.7) 
Past 5+ years -5.90 (2.2) -1.26 
0.97 
(-14.1 to 16.1) 
10.03 (3.9) -1.65 
-4.89 
(-23.3 to 13.5) 
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Table 3.8. Association between MHT status and change in physical functioning and 
activity scores over 3 years among postmenopausal women with multiple sclerosis (MS) 
who changed MHT use status by year 3. 
1  
Adjusted for the following baseline confounders: years since menopause, alcohol use (current and past 
drinking, with referent group as never drinker), and body mass index (<18.5 kg/m as underweight, 25 
kg/m
2 
≤ BMI < 30 kg/m
2
 as overweight, and ≥ 30 kg/m
2
 as obese, with the referent group as 18.5 kg/m
2 
≤ 
BMI < 25 kg/m
2
, or normal weight). 
 Δ Activities of Daily Living 
(3 year-baseline) 
Δ Physical Activity 
(3 year-baseline) 
  β-Coefficient  β-Coefficient 
Exposure 
Mean 
Change 
(Standard 
Deviation) 
Crud
e 
 
Adjusted
1
 
(95% 
Confidence 
Interval) 
Mean 
Change 
(Standard 
Deviation) 
Crude 
 
Adjusted
1
 
(95% Confidence 
Interval) 
MHT history       
    Never  -0.06 (0.4)   -1.75 (12.9)   
   Ever  0.0 (0.9) 0.06 
0.21  
(-0.2 to 0.6) 
-0.46 (0.5) -2.21 
1.20 
(-7.0 to 9.4) 
Unopposed 
estrogen duration 
      
< 10 years -0.40 (0.9) -0.58 
-0.24 
(-1.0 to 0.5) 
-5.03 (11.1) -4.01 
-6.69 
(-18.3 to 4.9) 
10+years 0.0 (0.0) -0.18 
0.32 
(-0.5 to 1.1) 
11.14 (15.4) 12.16 
7.84 
(-8.0 to 23.7) 
Recency of 
unopposed 
estrogen use 
      
Current -0.50 (1.0) -0.68 
0.22 
(-0.6 to 1.0) 
6.92 (13.3) 7.94 
6.16 
(-7.6 to 19.9) 
Past<9 years 0.0 (0.0) -0.18 
-0.32 
(-1.1 to 0.5) 
-10.44 (13.0) -9.42 
-10.45 
(-24.6 to 3.7) 
Past 10+ 
years ago 
0.0 (0.0) -0.18 
0.27 
(-1.1 to 1.6) 
0.0 (0.0) 1.02 
-3.48 
 (-27.2 to 20.2) 
Estrogen-plus-
progesterone 
duration 
      
< 5 years 0.20 (1.0) 0.49 
-0.15 
(-0.9 to 0.6) 
-2.18 (8.0) -5.72 
-1.18 
(-13.5 to 11.2) 
5-9 years 0.0 (0.0) 0.29 
-0.01 
(-1.4 to 1.4) 
0.0 (0.0) -3.54 
-3.00 
(-27.7 to 21.7) 
10+years 0.0 (0.0) 0.29 
-0.08 
(-1.5 to 1.3) 
-12.25 
(12.25) 
-15.79 
-13.15 
(-39.4 to 13.1) 
Recency of 
estrogen-plus-
progesterone use 
      
Current 0.0 (0.0) 0.29 
-0.56 
(-1.5 to 0.4) 
0.0 (0.0) -14.69 
-8.52 
(-25.6 to 8.5) 
Past < 5 
years 
0.29 (1.3) 0.57 
-0.19 
(-1.0 to 0.6) 
0.78 (3.3) -2.77 
1.40 
(-11.9 to 14.7) 
Past 5+ years 0.0 (0.0) 0.29 
0.20 
(-0.8 to 1.2) 
-11.15 (10.6) -3.54 
-5.98 
(-24.2 to 12.2) 
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Chapter 4: A Systematic Review of Pharmacological Pain 
Management in Multiple Sclerosis  
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Abstract 
Objective: To systematically review strategies for the reduction of pain in patients with 
multiple sclerosis (MS).   
Methods: Experimental studies published after 1965 were chosen for review by 
searching electronic databases (e.g. PubMed, Cumulative Index to Nursing and Allied 
Health Literature, Science Citation Index Expanded, Conference Proceedings Citation 
Index- Science, and clinicaltrials.gov) and bibliographies/citations of previously 
published reviews.  Studies were included if all participants were adults clinically 
diagnosed with MS, study sample was not restricted to participants with spasticity or 
trigeminal neuralgia, and participant-reported pain was a primary or secondary outcome 
measured with a validated tool.  Records were screened and methodological qualities of 
included studies were assessed independently by two reviewers under the supervision 
of another reviewer.   
Results: Fifteen studies met the inclusion and exclusion criteria for review; interventions 
included antidepressants, anticonvulsants, dextromethorphan/quinidine, cannabinoids, 
and opioids/opioid antagonists.  Meta-analyses were not performed due to few trials 
identified per treatment within these classes.  Four trials reported Class 1 evidence.  
Pain relief was reported compared to placebo for two of these trials (nabiximols: 
Cohen’s d: -0.61; dextromethorphan/quinidine: Cohen’s d: -0.22), but not reported in 
two other trials (nortriptyline: Cohen’s d: 0.76; nabixomols: Cohen’s d: 0.93).  For these 
trials, dizziness was the most commonly reported adverse event, followed by nausea 
and somnolence. 
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Conclusions: Nabiximols and off-label use of dextromethorphan/quinidine may be 
effective in reducing central neuropathic pain in MS.  More trials with rigorous design 
and reporting are needed to determine effective treatments for specific pain types 
presenting in people living with MS. 
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Introduction 
Multiple sclerosis (MS) is a chronic disease of the central nervous system that 
affects nearly 2.5 million people worldwide.1  The health-related quality of life for MS 
patients is strongly affected by the disease’s accompanying symptoms.17  Both chronic 
and acute pain have been cited as the most common symptoms amongst MS 
patients,73-75 with recent prevalence estimates as high as 83%.76  Sources of pain in MS 
are difficult to differentiate but certain pain syndromes are common in MS; trigeminal 
neuralgia77 presents in 5% and spasticity78 occurs in 50% of MS patients.76  The 
evidence for spasticity and trigeminal neuralgia pharmacological treatments in MS has 
been systematically reviewed;79-81 yet to our knowledge, no equivalent reviews have 
been published concerning MS pain unrelated to these two conditions.  Therefore, we 
systematically reviewed pain management strategies for the reduction of non-spastic 
and non-trigeminal neuralgic pain in MS patients.   
Methods 
We followed the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines82 for this review.  The objective of our search was to 
identify all experimental studies published since 1965 (publication year of the first 
established MS diagnosis criteria by Schumacher et al)83 which evaluated all pain 
management strategies in patients living with MS.  Electronic databases, including 
PubMed (1965 to November 16, 2012), the Cumulative Index to Nursing and Allied 
Health Literature (CINAHL) database (1997 to December 31, 2012), the Science 
Citation Index Expanded database and Conference Proceedings Citation Index- 
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Science (CPCI-S) database (1965 to December 31, 2012), and clinicaltrials.gov, were 
searched for relevant experimental studies.  The MEDLINE search strategy in Appendix  
was adapted for other databases using the following key words: MS AND pain AND 
therapy/management.  Additionally, the bibliographies of review articles found during 
our queries and the studies citing these reviews were searched to find all available 
experimental studies. 
Inclusion criteria 
Studies were considered eligible for inclusion in this review according to the 
following criteria: 1) sample consisted wholly of adult human participants with definite 
diagnoses of MS; 2) sample was not restricted to only those with spasticity or only those 
with trigeminal neuralgia; 3) patient-reported pain was measured as a primary or 
secondary outcome using a previously validated tool; 4) study was published in English 
and 5) study involved a pharmacological intervention.  Participants were adult humans 
aged 18 years or older with clinically diagnosed MS (according to the revised McDonald 
criteria3, original McDonald criteria,84 the Poser criteria,85 or the Schumacher criteria83).  
Studies were excluded if patient-reported pain was mentioned in the publication as an 
adverse event; this avoided the inclusion of disease-modifying therapies whose main 
intent was not pain management.  Validated tools to measure patient-reported pain 
included  the visual analogue scale (VAS),86 Patient’s Global Impression of Change 
(PGIC),87 McGill Pain Questionnaire (MPQ),88 the Body Pain subscale of the 36-item 
Medical Outcome Study Short Form (SF-36),36 and the numerical rating scale 
(NRS).89;87   
56 
 
Because spasticity and trigeminal neuralgia are common in patients living with 
MS, a study whose population consisted of a mix of spastic/trigeminal neuralgic patients 
and MS patients experiencing other types of pain was considered eligible for inclusion in 
this review.  Additionally, studies which did not evaluate comparison groups were also 
eligible for inclusion to allow for greater scope of review.   
Initially we identified 280 records using the search algorithm in Appendix, 
including 143 articles from PubMed, 43 articles from CINAHL, 34 articles and records of 
conference proceedings in the Web of Science, and 60 records from clinicaltrials.gov 
(Figure 4.1).  This pool yielded 50 relevant systematic reviews; after searching their 
bibliographies and citations, an additional 10 records were eligible for inclusion.  
Removing duplicates and screening records by title and abstract reduced the total 
number to 64 eligible records, with 15 included in our qualitative synthesis. 
Data extraction and synthesis 
Articles were independently selected and reviewed by R.J. and S.Y.; when 
opinions differed, consensus was reached between R.J., S.Y., and K.L.L.  Agreements 
between R.J. and S.Y. were strong with a kappa statistic of 0.795.  Data extracted 
included study type, population characteristics, pain management regimens, and mean 
patient-reported pain scores and standard deviations.  Study type consisted of parallel 
or crossover designs, presence and type of comparison group, mean study duration, 
and pain scale used.  Population characteristics included mean age, gender, type of 
MS, duration of disease, baseline use of pain medications, and baseline disability as 
measured by the Extended Disability Status Scale (EDSS).90  Finally, pain management 
regimens were evaluated for dose and duration of treatment.  For studies which 
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evaluated comparator groups, the average duration of treatment for comparison groups 
were also recorded.  Pain scores were recorded as mean differences between or within 
groups weighted by the inverse of the pooled standard deviation (Cohen’s d),91, 92 as this 
standardization allowed comparison of effect sizes independent of pain measurement 
tools.93  A negative Cohen’s d indicates a relative reduction in pain associated with a 
treatment versus a comparator.  For studies where the standard deviation was not 
reported or incalculable from the reported data, differences between scores were 
recorded. 
Finally, the methodological qualities of all studies included were examined using 
the principles recommended in the Cochrane Handbook for Systematic Review of 
Interventions94 and the levels of evidence espoused by the American Academy of 
Neurology.95  This included an assessment of the following: randomization sequence 
generation, allocation concealment, clear definition of primary outcome, 
inclusion/exclusion criteria, and standard treatment for intervention and comparator 
groups, and blinding/masking of participants, personnel and outcome assessors.   As 
this systematic review used previously published data, no ethical approval was sought. 
Results 
The 15 trials meeting our inclusion an d exclusion criteria are ranked according to 
class of evidence in Table 4.1.  Seven trials evaluated the intervention with a separate 
comparison group while 5 trials used a crossover design and 3 trials were not controlled 
(Table 4.2).  All except three trials examined participant-reported pain as the primary 
outcome.  The most common pain scales used were variations of the NRS and VAS; no 
58 
 
trials used the MPQ but two trials used the Modified Memorial Pain Assessment Card96 
and the Brief Pain Inventory short form (BPI-SF),97 respectively.  Major classes of 
pharmacological interventions included anticonvulsants, antidepressants, cannabinoids, 
dextromethorphan/quinidine, and opioids/opioid antagonists.  As no more than 3 trials 
were identified per pharmacological treatment within these classes, meta-analyses were 
not performed.  Table 4.3 provides additional information on study design and baseline 
characteristics for all included trials. 
Anticonvulsants 
Six trials evaluated the use of anticonvulsants to treat pain in participants living 
with MS; the different types of pharmacological interventions included levetiracetam,98, 99 
lamotrigine,100 gabapentin,101 pregabalin,102 and oxcarbamezapine.103  Levetiracetam at a 
maximum dose of 3000 mg/day was reported as effective in reducing pain scores when 
compared to placebo in both Class 2 and Class 3 trials; this reduction persisted when 
measured by the 11-point NRS98 and the 100 mm VAS99 (Cohen’s d: -0.52 and -1.36, 
respectively).  The most common adverse events for those participants in the treatment 
group included tiredness, dizziness and mental changes.   
In a Class 3 trial, lamotrigine100 was reported effective in reducing worst and least 
pain (Cohen’s d: -0.2 and -0.4, respectively) as measured by the BPI-SF, but ineffective 
in reducing average pain in comparison to placebo (Cohen’s d: 0.4); nausea was the 
most commonly reported adverse event at a maximum dose of 400 mg/day.  Class 4 
trials in gabapentin101 (maximum dose of 2400 mg/day) and pregabalin102 (maximum 
dose of 300 mg/day) also reported a reduction in pain scores, with adverse events 
including mental cloudiness, somnolence, and nausea.  Finally, oxcarbamezapine103 
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initiated at 150 mg/day and titrated to a maximum dose of 1200 mg/day reduced pain 
scores in one Class 4 trial (Cohen’s d: -3.7) with a low rate of adverse events. 
Antidepressants 
Two trials evaluated antidepressants (nortriptyline and duloxetine) to treat pain in 
participants living with MS.  While both varied in quality, both studies had similar 
inclusion criteria and allowed participants to concurrently use other stabilized pain 
medications with the experimental treatment.  Nortriptyline,104 when initiated at 10 
mg/day and titrated to a maximum dose of 50 mg/day, was not reported to be effective 
in comparison to transcutaneous electrical nerve stimulation (TENS; Cohen’s d: 0.76) in 
a Class 1 trial.  Duloxetine105 was reported to effectively reduce pain scores in 
participants of a Class 3 trial of central neuropathic pain (Cohen’s d: -0.44); duloxetine 
was initiated at 30 mg/day and titrated to a maximum dose of 60 mg/day.  Fewer and 
milder adverse events were reported for nortriptyline compared to duloxetine; for both 
antidepressants, adverse events included nausea, diarrhea, and somnolence.   
Cannabinoids 
The two types of cannabinoids assessed were nabixomols, an oromucosal spray 
containing 2.7 mg of delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD), 
and dronabinol, an oral capsule of 2.5 mg of THC.  Two Class 1 trials and one Class 3 
trial assessed nabixomols with differing results.  A Class 1 trial78 in participants 
experiencing central pain reported improvement in pain scores compared to placebo 
(Cohen’s d: -0.61); this effect was persistent in the Class 3 trial,106 which also recruited 
participants with central pain (Cohen’s d: -0.13).  Yet, the other Class 1 trial107 in 
nabixomols, which recruited participants experiencing spasticity, spasms, bladder 
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problems, tremor, and/or non-musculoskeletal pain, reported no improvement in pain 
compared to placebo (Cohen’s d: 0.93).  The Class 3 trial in dronabinol108 also reported 
improvement in pain scores compared to placebo for participants with central pain 
(Cohen’s d: -0.6).   
The occurrence of adverse events was similar for all four trials.  Dizziness was 
the most commonly reported event for any trial, experienced by 20% to 58% of 
participants in the intervention groups.  Other adverse events included 
fatigue/somnolence, vertigo, and headaches.  In one Class 1 trial in nabixomols,107 
burning at the site of application was reported by 26% of participants in the treatment 
group; because 23% of participants receiving placebo also reported this event, the 
authors hypothesized this was a result of the ethanol formulation of the oromucosal 
sprays.  Later studies78, 106 do not report this adverse event, indicating less irritating 
formulations may have been created. 
Dextromethorphan/Quinidine  
One Class 1 trial109 evaluated capsules containing 30 mg dextromethorphan (DM) 
and 30 mg quinidine(Q) in participants who had scored at least 13 points on the Center 
for Neurologic Study-Liability Scale (CNS-LS) at baseline.  While the treatment was 
intended for pseudobulbar affect, pain improvement was reported when compared to 
placebo (Cohen’s d: -0.22).  The most common adverse events reported were non-
vertiginous dizziness (26% of participants in the treatment group), nausea (22% of 
treatment group), and headache (16% of treatment group). 
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Opioids/opioid antagonists 
Two trials evaluated an opioid agonist (morphine) and an opioid antagonist 
(naltrexone) in separate placebo-controlled crossover studies.  A Class 3 trial in 
naltrexone110 at 4.5 mg/day reported a reduction in pain scores when compared to 
placebo (mean score difference between groups: -2.13).  A Class 4 trial in intravenous 
morphine111 also reported reduced pain scores compared to a saline placebo (Cohen’s 
d: -0.48).  Despite the differing effects of each drug, adverse events were similar 
between both trials.  The most common adverse event was sedation, with vivid 
dreaming an added effect of naltrexone.   
Quality assessment 
Of the 15 trials included in this systematic review, only 4 had Class 1 evidence; 
the majority of trials were Class 3 or Class 4 (Table 4.2).  One Class 4 trial111 did not 
employ randomization when allocating treatments and more than 30% of participants in 
one Class 3 trial were lost to attrition and adverse events.100  All controlled trials 
employed some blinding or masking methods, but 3 trials did not explicitly blind the 
physicians administering or overseeing treatment and 2 did not blind the outcome 
assessors.  In general, all studies included had poor reporting standards regarding 
allocation concealment techniques and compliance differences between treatment and 
comparison groups.  One Class 3 trial110 noted that 14% of participants were lost due to 
poor database management and survey followup. 
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Conclusions 
Pain is the symptom most commonly reported by people living with MS, yet few 
clinical trials have examined interventions for MS chronic pain with little consistency in 
treatment mechanisms.  To our knowledge, this review is the first to evaluate treatments 
for pain unassociated with spasticity and trigeminal neuralgia in MS.  Of the studies 
identified, the most common classes of drugs studied were anticonvulsants, 
antidepressants, cannabinoids, dextromethorphan/quinidine, and opioids/opioid 
antagonists.  
Our systematic review revealed Class 1 evidence supporting the use of 
nabixomols and dextromethorphan/quinidine for pain reduction in MS.  While Wade et 
al.107 indicated no effect on pain scores due to nabixomols, this may be due to the 
inclusion of participants with mixed pain types (including spasticity and non-
musculoskeletal pain).  When excluding participants with spasticity, Rog et al78 
demonstrated Class 1 evidence for nabixomols reducing pain scores.  While nabixomols 
are not currently approved for use in the US, it is approved for use in the United 
Kingdom where it has been shown to be effective in reducing pain in patients with 
MS.112  Additionally, Panitch et al109 demonstrated Class 1 evidence supporting off-label 
use of dextromethorphan/quinidine for pain reduction in MS.  Currently marketed as 
Nuedexta® (20 mg DM/10 mg Q) and approved by the US Food and Drug 
Administration for treatment of pseudobulbar affect,113 use of 
dextromethorphan/quinidine does not come without risks of QTc interval prolongation, 
falls, dizziness, headaches, diarrhea, and interactions with other medications.  Indeed, 
the risk of ventricular arrhythmias as a result of QTc interval prolongation led to a 
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dosage change from 30 mg DM/30 mg Q used by Panitch et al109 to its current market 
formulation.114  While the new formulation has not been studied exclusively in MS 
patients, a Phase III trial114 in a mixed sample of participants with amyotrophic lateral 
sclerosis and MS suggests greater pain improvement and fewer side effects.  Careful 
clinical consideration of risks and benefits of nabixomols and 
dextromethorphan/quinidine are warranted before prescribing.  In addition, the cost of 
treatment should be considered.  Though dextromethorphan/quinidine consists of over-
the-counter ingredients, current prices for a month’s supply range from $400 to $600.115 
We did not find evidence to support the use of nortriptyline in MS patients 
experiencing pain.  Nortriptyline has been shown to be very effective in treating 
neuropathic pain in other studies,116 yet did not reduce pain scores in the sole trial 
presented in this review.  This discrepancy may be due to the trial’s protocol of titrating 
nortriptyline up to a maximum dose of 50 mg/day,104 while other neuropathic pain trials 
have often titrated to much higher doses.  If nortriptyline is effective for treating chronic 
pain in MS at higher doses, the evidence-base is lacking. 
Our review did provide evidence consistent with literature on general neuropathic 
pain.  In particular, the evidence from Class 2 through 4 trials of gabapentin,117 
pregabalin,118 duloxetine,119 intravenous morphine,111 and naltrexone110 are supported by 
previous reviews.120, 121  As with Class 1 evidence, some reductions in pain occurred 
with treatment, but increases in gastrointestinal and central nervous system adverse 
events were non-trivial.   
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The strengths of our review lay in our search methodology, inclusion criteria, and 
rigorous review methodology.  Standardized effect sizes and classification of studies by 
methodological and reporting quality are provided to facilitate understanding.  Our 
inclusion criteria restricting the studies to chronic pain not associated with spasticity or 
trigeminal neuralgia allowed is novel.  Because such studies in the MS literature are 
scarce, we included uncontrolled clinical trials and pilot studies.  While the large effect 
sizes reported by the uncontrolled studies reflect an overestimation of the true treatment 
effect by not accounting for placebo effect, controlled studies are presented separately 
from the uncontrolled to aid interpretation.  Of the 15 trials presented in this review, only 
three did not evaluate patient-reported pain as a primary outcome.  The consistent 
effect sizes across multiple trials per drug (e.g. levetiracetam, nabixomols) indicate 
strength of evidence.  While publication bias may be a possibility, our search strategy 
was built to minimize this possibility.  Our search strategy included studies referenced in 
conference proceedings and search clinicaltrials.gov.  Indeed, our review included two 
Class 1 evidence trials which reported negative effects.   
The findings of this systematic review must be considered with a few caveats in 
mind.  Our review focused on pharmacological management of pain in MS; additional 
non-pharmacologic treatments may offer benefits but were beyond the scope of this 
review.  As evidenced by Chitsaz et al.,104 TENS may be more effective in reducing MS 
pain than nortriptyline.  Additionally, the relatively small number of trials in MS patients 
with chronic pain precludes our ability to make specific recommendations for treatment 
strategies.  Finally, our review did not reveal any studies of drug combinations.  In 
studies of general neuropathic pain, drug combinations, such as gabapentin and an 
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opioid, are more effective at reducing neuropathic pain than monotherapy.122  Thus, the 
extent to which drug combinations would be beneficial in patients with MS is unknown. 
In summary, our review identified nabiximols and off-label use of 
dextromethorphan/quinidine as promising treatments for chronic pain in MS.  Side effect 
profiles for both treatments include dizziness, nausea, and headaches, but patients 
report acceptable tolerability.114  Unfortunately, generic formulations are not available for 
either treatment and nabiximols is not approved for use in the United States.  While 
nabiximols and off-label use of dextromethorphan/quinidine might be effective, the 
evidence base is insufficient to establish how to choose an optimal therapy for particular 
patients.  In all but one study, the clinical studies were relatively short duration (<4 
months).  Long term assessment of the efficacy and safety of pharmacologic treatments 
of pain in MS patients is needed.  In the absence of evidence to help clinicians select 
one therapy over another,  clinicians and patients must careful consider available 
treatment regimens in the context of efficacy, risk of adverse events, cost, and clinical 
complexity of the patient (e.g. comorbid conditions and concomitant medication use).  
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Figure 4.1. Flow chart of the systematic review. 
 
280 records identified through 
database searching 
10 additional records identified 
through other sources
 a
 
18 duplicates removed 
272 records screened by 
title and abstract 
208 records excluded 
- 50 review articles
 a
 
- 159 records did not meet inclusion/exclusion 
criteria 
64 records screened by 
full-text for eligibility 
49 records excluded 
- 28 non-pharmacological interventions 
- 5 trials currently ongoing 
- 2 articles used the same sample population as 
studies already included 
- 14 articles did not meet inclusion/exclusion criteria  
15 records included in 
qualitative synthesis 
a
 Sources include the bibliographies and citing articles of the 50 reviews found through database searches. 
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Table 4.1. Included trials of pharmacological pain management for multiple sclerosis 
(MS) by evidence class and effect size. 
Citation  
 
Sample size,  
Pain management therapy and dose 
Pain measurement tool, 
Main findings 
 
Class 1 Evidence 
Rog, 2005 
 
 
 
 
N = 66 
 
Nabixomols  (Oromucosal spray, 5 weeks) 
On first day up to 4 sprays delivered in 2 
hours (2.7 mg THC/2.5 mg of CBD); 
participants advised to increase sprays up to 
48 sprays (THC 129.6 mg THC/120 mg CBD) 
in 24 hours. 
11-pt NRS 
 
Intervention mean score change (SD): -2.73 
(1.9)* 
Placebo mean score change (SD): -1.41 (1.7) 
Cohen’s d: -0.61 
Panitch, 2006 
 
 
 
N = 150 
 
Dextromethorphan/Quinidine (Capsule, 85 
days) 
Initiated and remained on 30mg DM/30mg Q 
every 12 hours throughout duration. 
Duration: 85 days 
5-pt NRS 
 
Intervention mean score change (SD): -0.4 
(0.88) 
Placebo mean score change (SD): -0.2 (0.86)  
Cohen’s d: -0.22 
Chitsaz, 2009 
 
 
  
N = 59 
 
Nortriptyline  (Pill, 8 weeks) 
Initiated at 10 mg/day for first 3 days; 
increased to 25mg/day for next 4 days; 
maximum dose (50 mg/day) continued for 
remaining weeks. 
10-pt VAS 
 
Intervention mean score change (SD): -1.6 
(2.0) 
Comparator mean score change (SD): -2.5 
(1.6) 
Cohen’s d = 0.76 
Wade, 2004 
 
 
N = 160 
 
Nabixomols  (Oromucosal spray, 6 weeks) 
Initiated at 2.7 mg THC/2.5 mg CBD per day 
or when necessary; titrated to maximum dose 
(120 mg THC/120 mg CBD) 
100-mm VAS 
 
Intervention mean score change: -11.4 
Placebo mean score change: -20.17 
Pooled SD: 9.4 
Cohen’s d: 0.93 
Class 2 Evidence 
Rossi, 2009 
 
  
N = 20 
 
Levetiracetam  (Tablet, 3 months) 
Initiated at 1000 mg/day for week 1; titrated 
up to maximum dose (3000 mg/day) at week 
4 and continued for remaining weeks 
100 mm VAS 
 
Intervention mean score change (SD): -45 (20) 
Placebo mean score change (SD): -15 (17) 
Cohen’s d: -1.36 
Class 3 Evidence 
Falah, 2012 
 
 
 
 
N = 30 
 
Levetiracetam (Tablet, 6 weeks) 
Initiated with 500 mg/day and titrated to 
maximum dose (3000 mg/day) for 15 days 
11-pt NRS 
 
Intervention mean score change (SD): 5.3 (2.0) 
Placebo mean score change (SD): 5.7 (1.8) 
Cohen’s d = -0.52 
NCT0075580
7 
 
 
 
N = 239 
 
Duloxetine  (Pill, 6 weeks) 
Initiated on 30 mg/day for 1 week; titrated to 
60 mg/day for remaining weeks 
11-pt NRS 
 
Group 1 mean score change (SD): -1.83 (1.73) 
Group 2 mean score change (SD): -1.07 (1.72) 
Cohen’s d: -0.44 
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Breuer, 2007 
 
 
 
 
N = 15 
 
Lamotrigine  (Pill, 13 weeks) 
Initiated with 25mg/day for weeks 1 and 2; 
increased to 50 mg/day (weeks 3 and 4), 
100mg/day (week 5), 200 mg/day (week 6), 
300 mg/day (week 7) up tp maximum dose at 
week 8 (400 mg/day) 
Final dose maintained for 3 weeks then dose-
tapering occurred for 2 weeks 
BPI Short Form 
 
Mean score changes (SD): Worst pain: -1.0 
(2.7), Average pain: 0.8 (4.0), Least pain : -0.8 
(2.0) 
 
Cohen’s d:  
Worst pain: -0.2 
Average pain: 0.4 
Least pain: -0.4 
NCT0039107
9 
 
 
 
N = 339 
 
Nabixomols  (Oromucosal spray, 14 weeks) 
Initiated at 2.7 mg THC/2.5 mg CBD, 8 to 12 
sprays per day; titrated to maximum dose 
(32.4 mg THC/30 mg CBD) 
11-pt NRS 
 
Group 1 mean score change (SD): -2.02 (2.15) 
Group 2 mean score change (SD): -1.89 (2.33) 
Cohen’s d: -0.13 
Cree, 2010 
 
 
 
N = 80 
 
Naltrexone  (Capsule, 8 weeks) 
Initiated and continued at 4.5 mg/day 
SF-36 Bodily Pain subscale 
 
Intervention mean score change: 5.49 
Placebo mean score change: 3.36 
Difference: -2.13 
Svendsen, 
2004 
N = 24 
 
Dronabinol  (Capsule, 15 to 21 days)  
Initiated on 2.5 mg/day, increased 2.5 mg 
every other day to maximum dose (10 
mg/day) 
11-pt NRS 
 
Group 1 median score change: -1.0  
Group 2 median score change: -1.5 
Median difference: −0.6 
Class 4 Evidence 
Kalman, 2002 
 
 
 
N = 14 
 
Morphine  (Infusion, at least 11 minutes) 
Initiated at rate of 1 mg/(kgBWh) until pain 
reduction > 50% on VAS; continued at this 
maximum dose for 10 min. 
100 mm VAS 
 
Intervention mean score change (SD): -21.4 
(19.0) 
Placebo mean score change (SD): -9.5 (14.7) 
Cohen’s d: -0.48 
Solaro, 2007 N = 12 
 
Oxcarbamezapine  (Pill, 3 months) 
Initiated at 150 mg/day and increased every 3 
days until achieved pain relief or  maximum 
dose (1200 mg/day) 
4-pt NRS 
 
Initial mean score (SD): 2.5 (0.5) 
Final mean score (SD): 0.2 (0.4) 
Cohen’s d: -3.7 
Solaro, 2009 N = 16 
 
Pregabalin  (Pill, 3 months) 
Initiated at 75 mg/day and increased every 3 
days until achieved pain relief or maximum 
dose (300 mg/day) 
4-pt NRS 
 
Initial mean score (SD): 2.4 (0.5) 
Final mean score (SD): 0.4 (0.7) 
Cohen’s d: -2.3 
Houtchens, 
1997 
N = 25 
 
Gabapentin  (Pill, 17 months) 
Initiated at 300 mg/day; titrated over 3 weeks 
to maximum tolerated dose (ranged from 300 
mg/day to 2400 mg/day) 
Modified Memorial Pain Assessment Card 
 
31.8% excellent relief (change of 5 to 9 pts) 
36.3% moderate relief (change of 2 to 4 pts) 
31.8% no relief (change of 1 to 0 pts) 
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Table 4.2. Quality Assessment of Included MS Pain Trials.   
 
 
 
Citation 
Treatment 
Allocation Blinding/Masking 
Parallel 
assignme
nt 
Complian
ce or 
attrition 
unlikely 
to 
introduce 
bias 
Comparabl
e Baseline 
characteri
stics 
Primary 
Outcom
e is 
Pain 
Rando
m-
ization 
Conceal
ed 
allocatio
n 
Patien
ts 
Physici
ans 
Outco
me 
Assess
ors 
Class 1 Evidence 
Rog, 2005 + + + + + + + + + 
Panitch, 2006 + + + + + + + + - 
Chitsaz, 2009 + + - - + + + + + 
Wade, 2004 + + + + + + + + - 
Class 2 Evidence 
Rossi, 2009 + ? + - - + + + + 
Class 3 Evidence 
Falah, 2012 + + + + + - - + + 
NCT00755807 + ? + + + + ? + + 
Breuer, 2007 + + + + + - + - + 
NCT00391079 + ? + + + + ? + + 
Cree, 2010 + ? + + + - - + - 
Svendsen, 
2004 
+ + + + + - + + + 
Class 4 Evidence 
Kalman, 2002 - ? + - - - + + + 
Solaro, 2007 n/a n/a n/a n/a n/a n/a + n/a + 
Solaro, 2009 n/a n/a n/a n/a n/a n/a + n/a + 
Houtchens, 
1997 
n/a n/a n/a n/a n/a n/a + n/a + 
+ = Yes; - = No; ? = Not reported; N/A = Not Applicable 
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Table 4.3. Description of included trials of pharmacological pain management for 
multiple sclerosis (MS). 
Citation 
 
Location, 
Clinicaltrials.gov 
ID, Funding 
source 
Inclusion criteria, Operational definition of 
comparison group, Duration of use 
 
Baseline Characteristics 
Class 1 Evidence 
Rog, 2005 
 
 
 
 
United Kingdom 
 
NCT01604265 
 
Funded by GW 
Pharmaceuticals 
1) Only central pain without a nociceptive cause of 
at least 3 months’ duration  
2) No spasticity or painless spasms alone or another 
non-central pain mechanism  
3) No contraindications or comorbidities 
4) No cannabinoid use in 7 days prior to screening 
5) Concomitant use of stabilized pain medications 
allowed  
 
Placebo: Oromucosal spray of ethanol:propylene 
glycol (50:50) 
Duration: 5 weeks 
Mean age (SD): 49.2 (8.3) yr 
21% men 
35% RRMS, 14% PPMS, 50% 
SPMS 
Mean MS duration (SD): 11.6 
(7.7) yr 
Mean EDSS score (SD): 5.9 
(1.3) 
Panitch, 2006 
 
 
 
 
United States, Israel 
 
Registration status is 
unknown 
 
Funded by Avanir 
Pharmaceuticals 
1) On first day of clinic visit, participant scored at 
least 13 points on the Center for Neurologic Study-
Liability Scale (CNS-LS). 
2) No concomitant use of antidepressants, 
monoamine oxidase inhibitors, anticoagulants, or 
certain other inhibitors or substrates for P450 2D6 or 
P450 3A4 
3) No contraindications or comorbidities 
 
Placebo: Identical capsules, no other description 
given 
Duration: 85 days 
Mean age: 45.0 yr 
17.3 % men 
Mean MS duration: 10.0 yr 
Chitsaz, 2009 
 
 
 
 
Iran 
 
Registration status 
unknown 
 
Funding not reported 
1) EDSS ≤ 6 
2) Natural disease course ≥ 2 years 
3) Discontinued use of opioids for duration of study, 
but concomitant use of non-opioid pain medication 
allowed. 
4) No contraindications 
 
Transcutaneous electrical nerve stimulation (TENS): 
Self-applied 3 times per day and when needed 
Initiated at 60 Hz and 40μs pulses for 20 to 30 
minutes; increased to maximum tolerated pulse 
strength and continued for remaining weeks 
Duration: 8 weeks 
Mean age (SD): 32.4 (7.8) yr 
25% men  
 
Wade, 2004 
 
 
 
 
United Kingdom 
 
NCT01610700  
 
Funded by GW 
Pharmaceuticals 
1) VAS score at least 50 for one symptom:  
spasticity, spasms, bladder problems, tremor, or non-
musculoskeletal pain 
2) No contraindications or comorbidities 
 
Placebo: Oromucosal spray of excipients, used daily 
and when necessary 
Duration: 6 weeks 
Mean age (SD): 50.7 (9.3) yr 
38.1% men 
24% spasticity  
 
 
 
Class 2 Evidence 
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Rossi, 2009 
 
 
 
Italy 
 
Registration status 
is unknown  
 
Funded by Italian MS 
Foundation, Italian 
Ministries of Health 
and Education, 
Universities, and 
Research, and UCB 
Pharmaceuticals 
1) Chronic neuropathic pain but not due to 
trigeminal neuralgia or other painful manifestations 
2) No MS relapse in 30 days prior to randomization 
3) No contraindications or comorbidities 
4) Concomitant use of stabilized pain medications 
not allowed 
 
Placebo: Tablets 
Duration: 3 months 
 
Mean age (SD): 37.6 (8.3) yr  
25% men 
85% RRMS, 5% PPMS, 10% 
SPMS  
Mean MS duration (SD): 7.2 
(5.9) yr 
Mean pain duration (SD): 8.2 
(5.8) yr 
Mean EDSS score (SD): 2.5 
(1.3) 
Class 3 Evidence 
Falah, 2012 
 
 
 
 
Denmark 
 
NCT00423527  
 
Not funded, UCB 
Pharmaceuticals 
sponsored monitoring 
throughout trial 
Inclusion criteria 
1) Pain in a body area with sensory abnormality 
on clinical exam/quantitative sensory exam 
corresponding to at least one lesion of the central 
nervous system  
2) Median total pain of at least 4 on an 11-point 
scale during 1 week off pain medication before 
randomization 
3) Concomitant use of stabilized pain medication 
not allowed 
 
Washout period: 1 week  
 
Placebo: Tablets 
Duration: 6 weeks 
Median age: 47 yr 
27% men 
60 % RRMS, 17% PPMS, 13% 
SPMS,  
Median MS duration: 8 yr 
Median pain duration: 5 yr 
Median EDSS score: 5 
NCT00755807 
 
 
 
United States, 
Belgium, Canada, 
and Poland 
 
NCT00755807 
 
Funded by Eli Lilly 
1) MS diagnosis at least 1 year prior to study 
2) Daily central neuropathic pain due to MS for at 
least 3 months prior to study 
3) No contraindications or comorbidities 
4) Concurrent stabilized pain medication allowed 
 
Placebo: Oral pill taken once daily 
Duration: 6 weeks 
 
Mean age (SD): 51.73 (9.4) yr 
25% men, 
64% RRMS, 11% PPMS, 21% 
SPMS,  
Mean MS duration (SD): 11.23 
(7.99) yr 
Mean pain duration (SD): 6.9 
(6.3) yr 
Mean EDSS score (SD): 4.0 
(1.89) 
 
Breuer, 2007 
 
 
 
 
United States 
 
Registration status is 
unknown 
 
Funded by 
GlaxoSmithKline 
1) Participant reported MS-related pain with 
neuropathic features for at least 3 months and scored 
at least 4 for any item on 11-point Neuropathic Pain 
Scale 
2) No central pain related to other conditions 
3) Did not experience 2 or more MS relapses within 
the prior 6 months and did not have rapidly 
progressive MS  
4) Did not receive corticosteroid treatment for MS in 
the 30 days prior to screening  
5) No contraindications or comorbidities 
6) Concomitant stabilized pain medication allowed  
 
Washout period: 2 weeks 
 
Placebo: Oral pill taken daily 
Duration: 13 weeks 
Mean age (SD): 49.3 (11.7) yr  
16.7%  men 
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NCT00391079 
 
 
 
Canada 
 
NCT00391079 
 
Funded by GW 
Pharmaceuticals 
1) Central neuropathic pain (CNP) for 3 or more 
months and expected to remain stable for the study 
duration 
2) Baseline pain score sum at least 24 
3) Pain not likely to be nociceptive, musculoskeletal 
(including spasms) peripheral neuropathic or 
psychogenic in origin, or due to trigeminal 
neuralgia. 
4) No contraindications or comorbidities 
 
Placebo: Oromucosal spray of excipients, 8 to 12 
sprays per day 
Duration: 14 weeks 
 
Mean age: 49 (10.47) yr 
32% men 
Mean MS duration (SD): 11.99 
(8.26) yr 
Mean pain duration (SD): 5.5 
(5.5) yr 
Cree, 2010 
 
 
 
United States 
 
NCT00501696 
 
Funded by private 
contributions from 
people living with 
MS 
1) Did not begin disease-modifying therapy in 3 
months prior to enrollment 
2) No currently on natalizumab or IFN and/or 
glatiramer acetate 
2) Not receiving treatment with chronic opiate 
agonists 
 
Washout period: 1 week  
 
Placebo: Capsules taken daily 
Duration: 8 weeks 
Mean age: 49 yr 
30% men, 
39% RRMS, 19% PPMS, 16% 
SPMS 
Svendsen, 
2004 
 
 
 
 
Denmark 
 
Registration status 
unknown  
 
Funded by Danish 
MS Society, private 
donations, and Solvay 
Pharmaceuticals 
1) Central pain in a body area for abnormal 
sensation to pinprick, touch, warmth or cold 
(evaluated in person) or quantitative sensory testing 
corresponding to at least one lesion in the central 
nervous system 
2) Pain at maximal pain site with score of at least 3 
points on 11-pt NRS 
3) No contraindications or comorbidities 
4) No marijuana use in 3 months prior to study 
5) Concurrent stabilized pain medication allowed 
 
Washout period: 15 to 21 days) 
 
Placebo: Capsules of sesame oil 
Duration: 15 to 21 days 
Median age: 50 yr 
42% men 
38% RRMS, 25% PPMS, 38% 
SPMS 
Median MS duration: 7.0 yr 
Median pain duration: 4.5 yr 
Median EDSS score: 6.0 
Class 4 Evidence 
Kalman, 2002 
 
 
 
 
Sweden 
 
Registration status 
is unknown  
 
Funded by Country 
Council of 
Ӧstergӧtland,  
Swedish Medical 
Research Council 
(MFR), The Bank of 
Sweden Tercentenary 
Foundation, and 
Swedish Association 
of Neurologically 
Disabled 
1) Constant, non-fluctuating central pain for at least 
6 months 
2) 100 mm VAS score > 30 at baseline 
3) No trigeminal neuralgia 
3) No contraindications or comorbidities 
 
Washout period: 10 min  
 
Placebo: Infusion of physiological saline at a rate of 
1 ml/(kgBWh) 
Duration: 20 min 
Mean age (SD): 54.9 (11.5) yr 
42.8% men, 
Mean MS duration (SD): 19.7 
(8.8) yr 
Mean pain duration (SD): 15.6 
(11.7) yr 
73 
 
Solaro, 2007 
 
 
 
Italy 
 
Registration status is 
unknown 
 
 Funding not reported 
1) Had painful paroxysmal symptoms (transient pain 
in any area with abrupt onset, duration from a few 
seconds to a 
few minutes, and with repetitive and stereotyped 
features) 
2) Non-responsive or intolerant to conventional 
medications 
3) Concomitant use of pain medications not allowed 
 
No comparison group 
Mean age (SD): 43.6 (10.9) yr 
31% men, 
83% RRMS, 8% PPMS, 8% 
SPMS 
33% trigeminal neuralgia 
Mean MS duration (SD): 7.3 
(4.9) yr 
Mean EDSS score (SD): 3.8 
(1.6) 
Solaro, 2009 
 
 
 
 
Italy 
 
Registration status is 
unknown 
 
Funding not reported 
1) Had painful paroxysmal symptoms (transient pain 
in any area with abrupt onset, duration from a few 
seconds to a 
few minutes, and with repetitive and stereotyped 
features) 
2) No relapses or worsening greater than 1 point on 
the EDSS scale in prior 3 months 
3) Previous treatment with conventional medication 
for paroxysmal pain 
4) No contraindications or comorbidities 
5) Concomitant use of neuropathic pain medications 
not allowed  
 
No comparison group 
Mean age (SD): 52 (12.4) yr 
38% men, 
44% RRMS, 19% PPMS, 38% 
SPMS  
Mean MS duration (SD): 11.9 
(8.0) yr 
Mean EDSS score (SD): 5.1 
(1.7) 
Houtchens, 
1997 
 
 
 
United States 
 
Registration status is 
unknown 
 
Funding not reported 
1) Attended the MS Clinic at the University of Utah 
School of Medicine or Georgetown University MS 
Center 
2) Concomitant use of pain medications allowed 
 
No comparison group 
Mean age: 45.8 yr 
32% men, 
60% RRMS, 32% PPMS, 8% 
SPMS  
Range of MS duration: 1 to 20 
yr 
Range of pain duration: 1 to 20 
yr 
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Chapter 5: A Systematic Review of Non-Pharmacological Pain 
Management in Multiple Sclerosis 
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Abstract 
Objective: To systematically review non-pharmacological strategies for the reduction of 
pain in patients with multiple sclerosis (MS).   
Data Sources: Experimental studies published after 1965 were chosen for review by 
searching electronic databases (e.g. PubMed, Cumulative Index to Nursing and Allied 
Health Literature, Science Citation Index Expanded, Conference Proceedings Citation 
Index- Science, and clinicaltrials.gov) and bibliographies/citations of previously 
published reviews. 
Study Selection: Studies were included if all participants were adults clinically 
diagnosed with MS, study sample was not restricted to participants with spasticity or 
trigeminal neuralgia, and participant-reported pain was a primary or secondary outcome 
measured with a previously validated tool.   
Data Extraction: Records were screened and methodological qualities of included 
studies were assessed independently by two reviewers under the supervision of another 
reviewer.  Pain scores were recorded as mean differences between or within groups 
weighted by the inverse of the pooled standard deviation (Cohen’s d). 
Data Synthesis: A total of 13 studies which met the inclusion and exclusion criteria 
were identified for review; interventions included education, electrical stimulation, and 
physical therapies.  Meta-analyses were not performed due to few trials identified per 
treatment within these classes.  Pain relief was reported compared to placebo for two 
trials in transcutaneous electrical nerve stimulation (TENS) with effect sizes of -3.37 and 
76 
 
-3.32, respectively.  Inconclusive pain relief was reported for other education and 
physical therapies. 
Conclusions: TENS may be effective in reducing central neuropathic pain in MS.  More 
trials with rigorous design and reporting are needed to determine effective treatments 
for specific pain types presenting in people living with MS. 
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Introduction 
Multiple sclerosis (MS) is a chronic disease of the central nervous system that 
affects nearly 2.5 million people worldwide.1  The health-related quality of life (HrQOL) 
for MS patients is strongly affected by the disease’s accompanying symptoms.17  Both 
chronic and acute pain have been cited as the most common symptoms amongst MS 
patients,73-75 with recent prevalence estimates as high as 83%.76  Sources of pain in MS 
are difficult to differentiate but certain pain syndromes are common in MS; trigeminal 
neuralgia77 presents in 5% and spasticity78 occurs in 50% of MS patients.76  The 
evidence for spasticity and trigeminal neuralgia treatments in MS has been 
systematically reviewed;79-81 yet to our knowledge, no equivalent reviews have been 
published concerning MS pain unrelated to these two conditions.  In particular, no 
reviews have focused on non-pharmacological pain management strategies.  Therefore, 
we systematically reviewed pain management strategies for the reduction of non-spastic 
and non-trigeminal neuralgic pain in MS patients.   
Methods 
Search Strategy 
We followed the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines82 in this review, we identified all experimental studies 
published since 1965 (publication year of the first established MS diagnosis criteria by 
Schumacher et al)83 which evaluated any pain management strategies in patients living 
with MS.  Electronic databases were searched, including PubMed (1965 to November 
16, 2012), the Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
78 
 
database (1997 to December 31, 2012), the Science Citation Index Expanded database 
and Conference Proceedings Citation Index- Science (CPCI-S) database (1965 to 
December 31, 2012), and clinicaltrials.gov.   
The MEDLINE search strategy in Appendix was adapted for other databases 
using the following key words: MS AND pain AND therapy/management.  We searched 
the bibliographies of review articles and the studies citing these reviews to find all 
available experimental studies. 
Inclusion criteria 
Studies were considered eligible for inclusion according to the following criteria: 
1) sample consisted wholly of adult human participants with definite diagnoses of MS; 2) 
sample was not restricted to only those with spasticity or only those with trigeminal 
neuralgia; 3) patient-reported pain was measured as a primary or secondary outcome 
using a previously validated tool; 4) study was published in English and 5) study 
involved a non-pharmacological intervention.  Participants were adult humans aged 18 
years or older with clinically diagnosed MS (according to the revised McDonald criteria3, 
original McDonald criteria,84 the Poser criteria,85 or the Schumacher criteria83).  Studies 
were excluded if patient-reported pain was mentioned in the publication as an adverse 
event; this avoided the inclusion of disease-modifying therapies whose main intent was 
not symptomatic pain management.  Validated tools to measure patient-reported pain 
included  the visual analogue scale (VAS),86 McGill Pain Questionnaire (MPQ),88 the 
Bodily Pain subscale of the 36-item Medical Outcome Study Short Form (SF-36),36 and 
the numerical rating scale (NRS).87, 89  Because spasticity and trigeminal neuralgia are 
common in patients living with MS, a study whose population consisted of a mix of 
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spastic/trigeminal neuralgic patients and MS patients experiencing other types of pain 
was considered eligible for inclusion.  Studies which did not evaluate comparison 
groups were eligible to allow for greater scope of review.   
We identified 280 records using the search algorithm in Appendix, including 143 
articles from PubMed, 43 articles from CINAHL, 34 articles and records of conference 
proceedings in the Web of Science, and 60 records from clinicaltrials.gov (Figure 5.1).  
This pool yielded 50 relevant systematic reviews; after searching their bibliographies 
and citations, an additional 10 records were eligible for inclusion.  Removing duplicates 
and screening records by title and abstract reduced the total number to 64 eligible 
records, with 13 included in our qualitative synthesis. 
Data extraction and synthesis 
Articles were independently selected and reviewed by R.J. and S.Y.; when 
opinions differed, consensus was reached between R.J., S.Y., and K.L.L.  Agreements 
between R.J. and S.Y. were strong with a kappa statistic of 0.795.  Data extracted 
included study type, population characteristics, pain management regimens, and mean 
patient-reported pain scores and standard deviations.  Study type consisted of parallel 
or crossover designs, presence and type of comparison group, mean study duration, 
and pain scale used.  Population characteristics included mean age, gender, type of 
MS, duration of disease, concomitant use of pain medications or management 
strategies, and baseline disability as measured by the Extended Disability Status Scale 
(EDSS).90  Finally, pain management regimens were evaluated for type, description, 
and duration of treatment.  For studies which evaluated comparator groups, the average 
duration of treatment for comparison groups were also recorded.  Pain scores were 
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recorded as mean differences between or within groups weighted by the inverse of the 
pooled standard deviation (Cohen’s d),91, 92 as this standardization allowed comparison 
of effect sizes independent of pain measurement tools.93  A negative Cohen’s d 
indicates a relative reduction in pain associated with a treatment versus a comparator.  
However, for the Bodily Pain subscale of the SF-36, a positive Cohen’s d indicates an 
improvement in pain-related quality of life or a reduction in pain associated with a 
treatment versus a comparator.  For these analyses, a Cohen’s d of 0.2 is considered a 
small effect, 0.50 a medium effect, and 0.80 a large effect.123  For studies where the 
standard deviation was not reported or incalculable from the reported data, differences 
between scores were recorded and labeled as such on the tables. 
Finally, the methodological qualities of all studies included were examined using 
the principles recommended in the Cochrane Handbook for Systematic Review of 
Interventions,94 which included an assessment of the following: randomization sequence 
generation, allocation concealment, clear definition of primary outcome, 
inclusion/exclusion criteria, and standard treatment for intervention and comparator 
groups, and blinding/masking of participants, personnel and outcome assessors.  As 
this systematic review used previously published data, no ethical approval was sought. 
Results 
The 13 trials meeting our inclusion and exclusion criteria are ranked according to 
type of intervention in Table 5.1.  Included studies are discussed in greater detail (e.g. 
inclusion criteria, baseline characteristics, type of comparison group) in Table 5.2.  All 
but one trial evaluated an intervention with separate comparison group(s), and the most 
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commonly used pain scale was the SF-36 Bodily Pain subscale.  Major types of 
interventions included education, electrical stimulation, and physical therapy.  As no 
more than 3 trials were identified per treatment within these groups, meta-analyses 
were not performed.   
Educational Interventions 
Five trials evaluated the use of educational interventions to help manage pain in 
participants living with MS; these included energy conservation courses (ECC),124-126 
chronic disease self-management courses (CDSMC),127 and hypnosis and/or cognitive 
restructuring courses (HCRC).128  ECC, originally meant for fatigue management, had 
little124, 126 to no125 improvement in pain-related quality of life, regardless of the presence 
of a comparison group.  CDSMC was reported as effective in reducing pain scores 
when compared to no treatment for participants on the waiting list, but ineffective when 
compared to no treatment for patients who did not participate.127  Overall, the greatest 
reduction in pain scores was shown for a combination of self-hypnosis and cognitive 
restructuring.128   
Electrical Stimulation 
Two trials129, 130 evaluated transcutaneous electrical nerve stimulation (TENS) in 
targeting chronic lower back pain amongst patients with MS.  While both studies 
measured pain with different scales (MPQ129 and 100 mm VAS130), both reported low 
frequency TENS at 4 Hz was more effective at reducing pain scores than high 
frequency TENS at 110 Hz.   
 
82 
 
Physical Therapy 
Of the five trials which evaluated different types of physical therapies, studies 
which evaluated outpatient rehabilitation,131-133 yoga and exercise,134 and robotic-
assisted gait training (RAGT)135 reported the greatest differences in pain scores.  The 
one trial which evaluated reflexology136 reported no improvement in pain when 
compared sham massage.  All physical treatments except for reflexology included 
educational sessions to address patients’ individualized needs and to teach improved 
physical function.  Both studies which evaluated directed outpatient rehabilitation 
showed improvement in pain-related quality of life compared to waiting list controls131 
and self-exercise.132  Additionally, physiotherapy in a warmer climate was shown to be 
more effective at reducing pain scores than physiotherapy in a colder climate (Cohen’s 
d: -0.12).133  While use of RAGT did not decrease pain scores compared to the walking 
control group (Cohen’s d: 0.61),135 the intervention also included healthcare-
professional-directed activities such as strengthening exercises, occupational therapy, 
and pool exercises. 
Quality assessment 
Of the 13 trials included in this systematic review, only one did not evaluate a 
comparator group (Table 5.3).  Two pilot studies125, 131 did not employ randomization 
when allocating treatments and attrition likely introduced bias in two more recent 
studies.127, 128  As these studies evaluated non-pharmacological treatments, most 
investigators did not adequately blind participants or researchers administering 
treatments.  Three studies128, 134, 135 did not use intention-to-treat analyses when 
evaluating outcomes. 
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Conclusions 
Pain is commonly reported by people living with MS, yet few clinical trials have 
examined interventions for MS chronic pain with consistency in treatment mechanisms.  
While pharmacological treatments for pain unassociated with spasticity and trigeminal 
neuralgia have been reviewed,137 this is the first review to evaluate non-pharmacological 
treatments for chronic pain in MS.  There were few studies found and most were of 
short duration.  Of the identified studies, the most common treatment types were 
education, electrical stimulation, and physical therapies.   
Of all pharmacological137 and non-pharmacological placebo-controlled trials in 
non-spastic and non-trigeminal neuralgic pain, low-frequency TENS (4 Hz, 200 μs) has 
the greatest reported reduction in pain scores, regardless of scoring method or duration 
of treatment.129, 138  Similar pain reduction has been reported by MS patients with 
spasticity139, 140 or using other types of electrical stimulation,141 which suggests TENS 
may be effective and cost-effective monotherapy for general MS pain.  Yet, TENS has 
not been extensively studied in patients with MS and only one trial104 has evaluated pain 
relief from TENS relative to a pharmacological agent.  Recent reviews142 support the use 
of TENS as part of a pain management package instead of monotherapy.  Despite this, 
Medicare does not cover TENS for patients with MS.143 
We did not find conclusive evidence to support the use of other education or 
physical therapies in MS patients experiencing pain.  However, those therapies which 
did not reduce pain scores often improved HrQOL and/or physical function.  Two 
studies which evaluated outpatient rehabilitation programs reported worsened pain 
scores but improvements in SF-36 scores and improved physical function, whether for a 
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duration of 12 weeks132 or one year.131  Yet, mind-body interventions such as hypnosis 
and/or cognitive restructuring128 and yoga134 were reported effective in treating pain but 
had little to no effect on HrQOL.  Similar differences have been found for other MS 
patients144 and for cancer-related pain.145  These results suggest clinicians and patients 
should also consider overall health when choosing pain management strategies. 
The strengths of our review lay in our search methodology, inclusion criteria, and 
review methodology.  Standardized effect sizes are provided to facilitate understanding.  
Because studies in chronic MS pain not associated with spasticity or trigeminal 
neuralgia are scarce, we included uncontrolled clinical trials and pilot studies.  While 
publication bias may be a possibility, our search strategy was built to minimize this by 
including studies referenced in conference proceedings and searches in 
clinicaltrials.gov.  Additionally, the consistent effect sizes across multiple trials per 
therapy (e.g. TENS) indicate strength of evidence.  The findings of this systematic 
review must be considered with a few caveats in mind.  Our review focused on non-
pharmacological management of pain in MS; additional pharmacologic treatments may 
offer benefits137 but were beyond the scope of this review.  The relatively small number 
of trials in MS patients with chronic pain precludes our ability to make specific 
recommendations for treatment strategies.   
In summary, our review identified TENS as a promising non-pharmacological 
alternative to drug therapy for chronic pain in MS.  Clinicians and patients must carefully 
consider the risks and benefits of supplanting pharmacological therapy with non-
pharmacological therapy such as TENS.  The clinical studies were of relatively short 
duration (up to one year).  Long term assessment of the efficacy and safety of TENS 
85 
 
and other non-pharmacologic treatments of pain in MS patients is needed.  Additionally, 
non-pharmacological pain scores are more often measured as a part of HrQOL scales 
(e.g. SF-36 Bodily Pain subscore), indicating non-pharmacological interventions are 
appropriate for a holistic treatment of neuropathic pain.  Thus clinicians and patients 
must weigh the importance of using a non-pharmacological therapy solely for pain 
management.  Physical and educational therapies which do not provide measurable 
pain relief may still improve physical function and HrQOL for patients living with MS.   
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Figure 5.1. Flow chart of the systematic review. 
 
280 records identified through 
database searching 
10 additional records identified 
through other sources
 a
 
18 duplicates removed 
272 records screened by 
title and abstract 
208 records excluded 
- 50 review articles
 a
 
- 159 records did not meet inclusion/exclusion 
criteria 
64 records screened by 
full-text for eligibility 
51 records excluded 
- 36 pharmacological interventions 
- 1 article used the same sample population as study 
already included 
- 14 articles did not meet inclusion/exclusion criteria  
13 records included in 
qualitative synthesis 
a
 Sources include the bibliographies and citing articles of the 50 reviews found through database searches. 
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Table 5.1. Included trials of non-pharmacological pain management for multiple sclerosis (MS) by treatment type and effect 
size. 
Citation  
 
Sample size, Study duration, Operational definition of 
pain management therapy 
Main findings 
Cohen’s d 
 
Education 
Barlow, 2009 
 
N = 216 
Duration: 4 months 
 
Chronic Disease Self-Management Course 
(2 hr/week for 6 weeks) 
Education regarding self-management principles, 
communication, and goal setting; delivered by lay 
instructors in community settings. 
10-pt NRS 
 
CDSMC mean change pain score (SD): -0.2 (2.8) 
Waiting List mean change pain score (SD): -0.4 (2.7) 
Informed non-attender mean change pain score (SD): -0.3 (2.8) 
 
Cohen’s d: 
CDSMC vs. Waiting List: -0.04 
CDSMC vs. Informed Non-attender: 0.04 
Finlayson, 2005 N = 29 
Duration: 6 sessions 
 
Energy Conservation Course 
(~1 hour/session for 6 sessions) 
Fatigue management education regarding living habits and 
communication; delivered via teleconference. 
SF-36 Bodily Pain Subscale 
 
Mean change pain score (SD): 6.9 (25.9) 
 
Cohen’s d: 0.27 
Jensen, 2010 
 
N = 22 
Duration: 16 hours 
 
Self-Hypnosis Training 
(~1 hr/session for 4 sessions) 
Clinician-induced hypnosis with suggestions for analgesia 
and comfort; participants urged to practice at home. 
 
Cognitive Restructuring 
(~1 hr/session for 4 sessions) 
Education about role of cognition in pain, coping skills, and 
maintenance of skills. 
 
Hypnosis/Cognitive Restructuring 
(~1 hr/session for 4 sessions) 
Combination of both methods above to reinforce skills and 
increase sense of pain control. 
10-pt NRS 
 
Hypnosis mean change pain score (SD): -0.9 (1.7) 
Cognitive mean change pain score (SD): -0.4 (1.9) 
Hyp/Cog mean change pain score (SD): -1.58 (1.7) 
Education mean change pain score (SD): -0.06 (1.7) 
 
 
Cohen’s d: 
Hypnosis: -0.49 
Cognitive: -0.18 
Hypnosis/Cognitive: -0.89 
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Mathiowetz, 2001 
 
 
N = 54 
Duration: 19 weeks  
 
Energy Conservation Education 
(2 hr sessions/week, 6 weeks) 
Fatigue management course regarding living habits and 
communication. 
SF-36 Bodily Pain Subscale 
 
Education mean change pain score (SD): -0.6 (23.5) 
Control mean change pain score (SD): 4.6 (25.0) 
 
Cohen’s d: -0.19 
Mathiowetz, 2005 
 
N = 169 
Duration:12 weeks 
 
Energy Conservation Education 
(2 hr sessions/week, 6 weeks) 
Fatigue management course regarding living habits and 
communication. 
SF-36 Bodily Pain Subscale 
 
Education mean change pain score: 2.69 
 
Cohen’s d: 0.18 
 
Electrical Stimulation 
Al-Smadi, 2003 
 
 
N = 15 
Duration:10 weeks 
 
Low-frequency TENS  
(4 Hz, 200 μs) 
Applied for 45 minutes 3 times/week for 6 weeks, and as 
needed. 
 
High-frequency TENS 
(110 Hz, 200 μs) 
Applied for 45 minutes 3 times/week for 6 weeks, and as 
needed. 
McGill Pain Questionnaire 
 
Low freq TENS mean change pain score (SD): -13.6 (4.1) 
High freq TENS mean change pain score (SD): 0.3 (4.1) 
Placebo TENS mean change pain score (SD): 0.2 (3.5) 
 
Cohen’s d: 
Low freq TENS: -3.37 
High freq TENS: 0.02 
Warke 2006 
 
N = 90 
Duration:32 weeks 
 
Low-frequency TENS  
(4 Hz, 200 μs for 45 minutes) 
Applied twice daily for 6 weeks and as needed. 
 
High-frequency TENS 
(110 Hz, 200 μs for 45 minutes) 
Applied twice daily for 6 weeks and as needed. 
100 mm VAS 
 
Low freq TENS mean change pain score: -20.76 
Hgh freq TENS mean change pain score: -8.21 
Placebo TENS mean change pain score: -17.44 
 
Mean Difference: 
Low freq TENS: -3.32 
High freq TENS: 9.23 
 
Physical Therapy 
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Di Fabio, 1997 
 
N = 31 
Duration: 1 year 
 
Outpatient Rehabilitation 
(5 hours/day, 1 day/week) 
Physical and occupational therapy, structured recreational 
experiences, and counseling. 
SF-36 Bodily Pain Subscale 
 
Outpatient Rehabilitation effect size: 0.16 
Waiting List Control effect size: -0.03 
 
Effect size difference: 0.19 
Hughes, 2009 
 
N = 71 
Duration: 10 weeks 
 
Reflexology 
(45 min/week) 
Pressure massage sequences stimulating key reflex points 
on feet associated with pain throughout body. 
10 mm VAS 
 
Reflexology median pain score difference: 3 
Placebo median pain score difference: 3 
 
Median value difference: 0 
Oken, 2004 
 
N = 69 
Duration: 6 months 
 
Yoga Sessions 
(90 min/week) 
Iyengar yoga with 19 instructed poses; held for up to 30 
sec with 30 sec to 1 min rest period between; all poses 
supported by chair or leaning against wall. 
 
Aerobic Exercise Sessions 
(1 class/week and home exercise) 
Recumbent/stationary bicycling or using a Swiss ball; kept 
moderate pace (participants able to converse while 
exercising) until stopped due to fatigue/exacerbated 
symptoms/reached 1 hour. 
SF-36 Bodily Pain Subscale 
 
Yoga mean change pain score (SD): -1.4 (18.6) 
Exercise mean change pain score (SD): 15.7 (15.5) 
Control mean change pain score (SD): 3.8 (25.7) 
 
Cohen’s d: 
Yoga: -0.22 
Exercise: 0.87 
Patti, 2002 
 
N = 111 
Duration: 12 weeks 
 
Outpatient Rehabilitation 
(50 to 60 min/day, 6 days/week) 
First 6 weeks were instruction; next 6 weeks were self-
executed physiotherapy, occupational therapy, speech 
therapy, group therapy, and other personalized therapy. 
SF-36 Bodily Pain Subscale 
 
Rehabilitation mean change pain score (SD): 14.9 (20.0) 
Self-exercise mean change pain score (SD): -0.1 (0.6) 
 
Cohen’s d: 0.91 
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Smedal, 2010 
 
N = 60 
Duration: 18 months 
 
Physiotherapy in Hakadal, Norway 
(60 min/day, 4 weeks) 
Physiotherapy focused on improving patient’s own 
movement control; measurements taken after 6 months of 
followup. 
10-pt NRS 
 
Norway mean change pain score (SD): 0.5 (2.6) 
Spain mean change pain score (SD): 0.2 (2.7) 
 
Cohen’s d: 
Spain vs. Norway: -0.12 
Vaney, 2012 
 
N = 67 
Duration: 3 weeks 
 
Robotic-Assisted Gait Training 
(30 min/session, 9 sessions) 
Support began at 50% of body weight then reduced after 
observing gait pattern; also included strengthening 
exercises, horseback riding, pool exercises and 
occupational therapy. 
10 mm VAS 
 
RAGT mean change pain score (SD): 1.0 (2.68) 
Walking group mean change pain score (SD): -0.70 (2.91) 
 
Cohen’s d: 0.61 
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Table 5.2. Description of included trials of pharmacological pain management for multiple sclerosis (MS). 
Citation  
 
Location, 
Registration 
ID, Funding 
Inclusion criteria, Study type, Operational definition of comparison 
group 
Baseline Characteristics 
 
Education 
Barlow, 
2009 
 
 
United 
Kingdom 
 
Registration 
status unknown  
 
Funded by UK 
MS Society 
Inclusion criteria 
1) Able to understand and participate in English 
 
Parallel assignment 
 
Waiting List Controls 
Included those on waiting list 
 
Informed Non-Attenders 
Aware of research and course, yet indicated they did not want to attend 
Mean age (SD): 51.1 (11.1) yr 
27.3% men, 
Mean MS duration (SD): 12 (9.3) yr 
Finlayson, 
2005 
 
 
USA 
 
NCT00591721 
 
Funded by 
University of 
Illinois 
Inclusion criteria 
1) Fatigue Severity Scale score ≥ 4 
2) No cognitive impairments according to Blessed Orientation Memory 
Concentration test 
 
Uncontrolled 
Mean age (SD): 47 (9.6) yr 
17.2% men, 
62.1% RRMS, 3.4% PPMS, 17.2% SPMS,  
Mean MS duration (SD): 9.8 (5.1) yr 
Mean symptom duration (SD): 14 (6.7) yr 
Jensen, 
2010 
 
 
USA 
 
NCT00621374 
 
Funding 
information not 
provided 
Inclusion criteria 
1) 10-pt NRS chronic pain score ≥ 4 for at least 6 months 
2) Telephone Interview of Cognitive Status score > 20 
3) In counseling/psychotherapy ≤ 1 session/week 
4) No psychiatric hospitalizations, hypnosis, cognitive behavioral therapy, 
or active suicidal ideation in past 6 months  
Crossover 
 
Education Control 
(~1 hr/session for 4 sessions) 
Education on scope of pain in MS patients and management strategies; 
specific coping skills not taught. 
Mean age: 52.6 yr 
20% men 
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Mathiowet
z, 2001 
 
. 
USA, 
 
Registration 
status unknown  
 
Funding 
information not 
provided 
Inclusion criteria 
1) Fatigue Severity Scale score ≥ 4 
2) Community dwelling 
3) Received personal care or homemaker services ≤ 10 hrs/week 
4) Not in other rehabilitation programs 
5) Stabilized concomitant fatigue treatments allowed 
 
Crossover  
Duration of washout period: 6 weeks  
 
Control Support Group 
(2 hr sessions/week, 6 weeks) 
Discussed living with MS with no mention of fatigue management 
Mean age (range): 50 (31 to 74) yr 
33% men, 
36% RRMS, 22% PPMS, 13% SPMS,  
Mean MS duration (range): 9.5 (1 to 34) yr 
Mathiowet
z, 2005 
 
 
USA 
 
Registration 
status unknown  
 
Funding 
information not 
provided 
Inclusion criteria 
1) Fatigue Severity Scale score ≥ 4 
2) Community dwelling 
3) Passed 3 of 4 subsets of Neuropsychological Screening Battery for MS 
 
Crossover 
 
Control Period 
(6 weeks) 
No intervention, so washout period not used. 
Mean age (SD): 48.3 (8.4) yr 
17.2% men, 
61.5% RRMS, 5.9% PPMS, 18.9% SPMS,  
Mean MS duration (SD): 9.5 (7.4) yr 
Mean symptom duration (SD): 14.9 (9.7) yr 
 
Electrical Stimulation 
Al-Smadi, 
2003 
 
 
Northern 
Ireland 
 
Registration 
status unknown  
 
Funding 
information not 
provided 
Inclusion criteria 
1) Chronic lower back pain for ≥ 3 months 
2) No contraindications to transcutaneous electrical nerve stimulation 
(TENS), analgesic abuse, or sacral pressure ulcers 
3) Stabilized concomitant pain treatments 
 
Parallel assignment 
 
Placebo TENS 
Used same machinery with no frequency 
No information provided 
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Warke 
2006 
 
 
Northern 
Ireland 
 
Registration 
status unknown  
 
Funded by the 
MS Society of 
Great Britain 
and Northern 
Ireland 
Inclusion criteria 
1) Chronic lower back pain for ≥ 3 months 
2) No contraindications to transcutaneous electrical nerve stimulation 
(TENS), analgesic abuse, or sacral pressure ulcers 
3) Stabilized concomitant pain treatments allowed 
 
Parallel assignment 
 
Placebo TENS 
Used same machinery with no frequency 
Mean age: 47.4 yr 
23.3% men, 
Mean MS duration: 10.7 yr 
Mean pain duration: 10.4 yr  
 
Physical Therapy 
Di Fabio, 
1997 
 
 
USA 
 
Registration 
status unknown  
 
Funding 
information not 
provided 
Inclusion criteria 
1) Progressive MS course 
2) EDSS score between 5 and 8 
 
Parallel assignment 
 
Waiting List Control 
On waiting list for treatment, not receiving outpatient rehabilitation 
Mean age: 47.4 yr  
19.4% men, 
Mean MS duration: 15.5 yr 
 
Hughes, 
2009 
 
 
Northern 
Ireland 
 
Registration 
status unknown  
 
Funded by U.S. 
National 
Multiple 
Sclerosis 
Society 
Inclusion criteria 
1) EDSS score ≤ 7.5 
2) Pain VAS score > 4 
3) No previous experience with reflexology 
 
Parallel assignment 
 
Placebo 
(45 min/week) 
Standardized foot massage with same sequence as treatment, but 
avoided key reflex points. 
Mean age: 51.5 yr 
16.9% men, 
39.4% RRMS, 11.3% PPMS, 26.8% SPMS,  
Mean MS duration: 12.5 yr 
Mean EDSS score: 6.0 
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Oken, 
2004 
 
 
USA 
 
Registration 
status unknown  
 
Funding 
information not 
provided 
Inclusion criteria 
1) EDSS score < 6.0 
2) No comorbidities or cognition impairment 
3) Did not perform yoga/tai chi in past 6 months 
4) Did not regularly perform aerobic exercise for > 30 min/day 
 
Parallel assignment 
 
Waiting List Controls 
Received no intervention. 
 
Mean age: 49.0 yr 
5.8% men, 
Mean EDSS score: 2.0 
 
Patti, 
2002 
 
 
Italy 
 
Registration 
status unknown  
 
Funding 
information not 
provided 
Inclusion criteria 
1) EDSS score between 4.0 and 8.0 
2) Mini-Mental State Exam score > 24 
3) No comorbidities or contraindications 
4) No rehabilitation, MS disease-modifying drugs, or other experimental 
drugs 6 months prior to study 
 
Parallel assignment 
 
Self-exercise Program 
Control group performed self-exercise program at home for 12 weeks. 
 
Mean age: 45.6 yr 
42.3% men,  
Mean MS duration: 17.2 yr 
Mean EDSS score: 6.2 
 
 
Smedal, 
2010 
 
 
Norway and 
Spain 
 
NCT01057719  
 
Funded by 
Oslo University 
Hospital, 
Haukeland 
University 
Hospital, and 
Western 
Regional 
Health 
Authority 
Inclusion criteria 
1) EDSS score of 4.0 to 6.5 
2) No past experiences with heat intolerance or excessive fatigue 
3) Non-severe cognitive dysfunction 
4) No comorbidities 
 
Crossover 
Washout period duration: 6 months 
 
Physiotherapy in Tenerife, Spain 
(60 min/day, 4 weeks) 
Physiotherapy focused on improving patient’s own movement control; 
measurements taken after 6 months of followup. 
Mean age (SD): 48.5 (9.0) yr 
40% men, 
63.3% RRMS, 5% PPMS, 31.7% SPMS,  
Mean EDSS score (SD): 4.5 (1.5) 
 95 
 
Vaney, 
2012 
 
 
Switzerland 
 
Registered in 
Switzerland: 
ISRCTN69803
702  
 
Funded by 
Berner Klinik 
Montana, 
ReSAR/HES-
SO of 
Switzerland 
Inclusion criteria 
1) EDSS score between 3.0 and 6.5 
2) Able to walk 14 meters with or without assistive devices 
3) Non-severe osteoporosis or scoliosis 
4) Even leg lengths 
5) No comorbidities 
 
Parallel assignment 
 
Walking Group 
(30 min/session, 9 sessions) 
Walked in a group with physiotherapist, in gym, or on uneven ground 
outdoors. 
Mean age: 56.3 yr 
Mean EDSS score: 5.8 
 
  
 96 
 
Table 5.3. Quality Assessment of Included MS Pain Trials.   
 Treatment 
Allocation 
Blinding        
 
 
 
Citation 
Randomizat
ion 
 
Blinded 
allocati
on 
Patien
ts  
Physicia
ns 
Outcom
e 
Assesso
rs 
Comparis
on group 
Primar
y 
Outco
me as 
Pain 
Complian
ce 
unlikely 
to 
introduce 
bias 
Attritio
n 
unlikely 
to 
introdu
ce bias 
Compara
ble 
follow-up 
time 
Intenti
on to 
Treat 
Analys
is 
Baseline 
characterist
ics 
comparable 
Barlow, 
2009 
+ + - - ? + - ? + + + - 
Finlayson
, 2005 
N/A N/A N/A N/A N/A - - + - N/A + N/A 
Jensen, 
2010 
+ ? ? ? + + + ? + + - + 
Mathiowe
tz, 2001 
- ? ? ? ? + - - - + + + 
Mathiowe
tz, 2005 
+ ? - - ? + - - - + + + 
Al-Smadi, 
2003 
+ + + - + + + - - + + ? 
Warke 
2006 
+ + + - + + + - - + + + 
Di Fabio, 
1997 
- N/A - - ? + - - - + + + 
Hughes, 
2009 
+ + + - + + + - - + + + 
Oken, 
2004 
+ + - - + + - - - + - + 
Patti, 
2002 
+ + + + + + - - - + + + 
Smedal, 
2010 
+ ? - - - + - - - + + + 
Vaney, 
2012 
+ + - - - + - - - + - + 
+ : Present; - : Not Present; ? : Not Reported; N/A : Not Applicable 
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Appendix  
 
MEDLINE search strategy 
 
(1965/01/01:2012/11/16[dp]) AND (Clinical Trial[pt] OR Randomized Controlled Trial[pt] 
OR Controlled Clinical Trial[pt] OR trial*[all] OR intervention*[all]) AND (((multiple 
sclerosis[majr]) OR ("multiple sclerosis"[tiab]) OR multiple sclerosis[all]) NOT (trigeminal 
neuralgia[mh]) NOT (muscle spasticity[mh])) AND (pain[majr] OR “pain”[tiab] OR 
(pain[mh] NOT chemically induced[sh]) OR (pain management[mh] OR pain 
measurement[mh])) 
 
 
 
 
1
Filters for human- and English-only studies were not applied in this algorithm to capture all available 
articles in the database, including newer, non-indexed articles.  Articles were later screened to exclude 
non-human studies (0 articles found) and non-English publications (14 articles found).
 109 
 
 
 
 
Vita 
 
 
Rachel Hannah Jawahar was born June 24, 1983 in Boonton, New Jersey and is a 
United States citizen.  She graduated from Plainview-Old Bethpage John F. Kennedy 
High School, Plainview, New York in 2001.  She received her Bachelor of Science in 
Engineering from Cornell University, Ithaca, New York in 2007.  She received a Masters 
of Public Health in Epidemiology from New York Medical College, Valhalla, New York in 
2010. 
 
HONORS AND AWARDS 
2011, Summer Fellow, F.D.A. Medical Device Fellowship Program 
2009, Popper Scholar Grant, Robert L. Popper Hudson Valley Health Fund, NY 
2004, Research Experience for Undergraduates Award, National Science Foundation 
2001, Highest Honors, NY Intel Science Talent Search  
 
 
PROFESSIONAL AND RESEARCH POSITIONS 
2013   Graduate Research Assistantship, Virginia Commonwealth University 
Dept. of Pharmacotherapy & Outcomes Science 
Mentor:  Amy L. Pakyz, Ph.D,  
 
2012  Contractor, Pfizer, New York, NY 
  Global Health Economics Outcomes Research, Global Market Access 
  Supervisor: Arthi Balachandran, Ph.D. 
 
 110 
 
2012   Graduate Research Assistantship, Virginia Commonwealth University 
Division of Epidemiology, Dept. of Family Medicine and Population Health 
Mentor:  Kate L. Lapane, Ph.D,  
 
2011  Fellow, U.S. Food and Drug Administration 
  Centers for Device and Radiological Health/OSB/EDPI/EERB2 
  Supervisor: Mary Beth Ritchey, Ph.D. 
 
2010  Teaching Assistant, Virginia Commonwealth University 
Division of Epidemiology, Dept. of Family Medicine and Population Health 
Mentor:  Saba W. Masho, M.D.  
 
2009  Program Evaluator, My Sister’s Place, White Plains, NY 
  Supervisor: Bincy Jacob 
 
2005  Undergraduate Researcher, Cornell University 
  Research Experience for Undergraduates, National Science Foundation 
  Mentor: Clifford Pollock, Ph.D. 
 
2000  Researcher, State University of New York at Stony Brook 
  Mentor: Michael A. Bender, Ph.D. 
 
 
PUBLICATIONS 
Jawahar R, Oh U, Yang S, Lapane KL.  A systematic review of pharmacological pain 
management in multiple sclerosis.  Under review in Neurology. 
 
Lapane KL, Yang S, Brown MJ, Jawahar R, Pagliasotti C, Rajpathak S.  Sulfonylureas 
and risk of falls and fractures: a systematic review.   Drugs Aging.  2013 Apr 23. 
 
Yang S, Jawahar R, McAlindon TE, Eaton CB, Lapane KL.  Racial differences in 
symptom management approaches among persons with radiographic knee 
osteoarthritis. BMC Complement Altern Med. 2012 Jul 6;12:86. 
 
Jawahar R, Yang S, Eaton CB, McAlindon TE, Lapane KL.  Gender-specific correlates 
of complementary and alternative medicine use among people with radiographically-
confirmed knee osteoarthritis. J Womens Health (Larchmt). 2012 Oct; 21(10):1091-9. 
 
 
 
 111 
 
PRESENTATIONS 
Jawahar R, Yang S, Lapane KL, Eaton CB. (2011, November) Approaches to pain 
management in women with osteoarthritis.  Poster presented at 139th Annual Meeting 
of the American Public Health Association, Washington, DC. 
 
Jawahar R, Yang S, Lapane KL, Eaton CB. (2011, August) Risky NSAID use in adults 
with osteoarthritis.  Poster presented at 27th Annual Scientific Meeting of the 
International Society for Pharmacoepidemiology, Chicago, IL. 
 
Jawahar R, Yang S, Lapane KL, Eaton CB. (2011, March) Pain management in women: 
Are conventional treatments enough?  Poster presented at 7th Annual VCU Women’s 
Health Research Day, Richmond, VA. 
 
 
 
 
 
 
 
